

# **APPENDIX 2**

**Preliminary Cumulative  
Hazard and Dose-Response Assessment for Organophosphorus Pesticides:**

**Determination of Relative Potency  
and Points of Departure  
for Cholinesterase Inhibition**

## **Appendix 2**

### **Table of Contents**

<b>Abbreviations</b> .....	Appendix 2 - Page 1
<b>Key to Figures in Appendix 2</b> .....	Appendix 2 - Page 2
<b>Acephate</b> .....	Appendix 2 - Page 4
Acephate Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 4
Acephate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 5
Acephate Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 7
Acephate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 8
Acephate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 11
Acephate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 14
Acephate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 15
Acephate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 16
Acephate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 18

<b>Azinphos Methyl</b> .....	Appendix 2 - Page 20
Azinphos Methyl Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 20
Azinphos Methyl Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 21
Azinphos Methyl Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 22
Azinphos Methyl Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 23
Azinphos Methyl Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 24
Azinphos Methyl Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 25
Azinphos Methyl Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 26
Azinphos Methyl Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 27
Azinphos Methyl Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 28
 <b>Bensulide</b> .....	Appendix 2 - Page 29
Bensulide Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 29
Bensulide Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 30
Bensulide Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 31
Bensulide Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 32
Bensulide Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 33
Bensulide Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 34
Bensulide Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 35
Bensulide Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 36
Bensulide Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 37
 <b>Chlorpyrifos</b> .....	Appendix 2 - Page 38
Chlorpyrifos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 38
Chlorpyrifos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 39
Chlorpyrifos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 41
Chlorpyrifos Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 42
Chlorpyrifos Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 43
Chlorpyrifos Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 44
Chlorpyrifos Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 46
Chlorpyrifos Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 48
Chlorpyrifos Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 49

<b>Diazinon</b> .....	Appendix 2 - Page 50
Diazinon Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 50
Diazinon Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 51
Diazinon Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 53
Diazinon Figure 2. - Brain Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 54
Diazinon Figure 3. - Brain Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 55
Diazinon Figure 4. - Plasma Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 56
Diazinon Figure 5. - Plasma Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 57
Diazinon Figure 6. - RBC Female Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 58
Diazinon Figure 7. - RBC Male Results of Dose-Reponse Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 59
 <b>Dichlorvos</b> .....	Appendix 2 - Page 60
Dichlorvos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 60
Dichlorvos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 61
Dichlorvos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 62
Dichlorvos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 63
Dichlorvos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 64
Dichlorvos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 65
Dichlorvos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 66
Dichlorvos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 67
Dichlorvos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 68
 <b>Dimethoate</b> .....	Appendix 2 - Page 69
Dimethoate Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 69
Dimethoate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 70
Dimethoate Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 71
Dimethoate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 72
Dimethoate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 73
Dimethoate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 74
Dimethoate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 75
Dimethoate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 76
Dimethoate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 77

<b>Disulfoton</b> .....	Appendix 2 - Page 78
Disulfoton Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 78
Disulfoton Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 79
Disulfoton Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 81
Disulfoton Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 82
Disulfoton Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 83
Disulfoton Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 84
Disulfoton Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 85
Disulfoton Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 86
Disulfoton Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 87
<b>Fenamiphos</b> .....	Appendix 2 - Page 88
Fenamiphos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 88
Fenamiphos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 89
Fenamiphos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 91
Fenamiphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 92
Fenamiphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 93
Fenamiphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 94
Fenamiphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 95
Fenamiphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 96
Fenamiphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 97
<b>Fosthiazate</b> .....	Appendix 2 - Page 98
Fosthiazate Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 98
Fosthiazate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 99
Fosthiazate Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 101
Fosthiazate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 102
Fosthiazate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 104
Fosthiazate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 106
Fosthiazate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 108
Fosthiazate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 110
Fosthiazate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 112

<b>Malathion</b> .....	Appendix 2 - Page 114
Malathion Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 114
Malathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 115
Malathion Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 116
Malathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 117
Malathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 120
Malathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 123
Malathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 124
Malathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 125
Malathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 126
 <b>Methamidophos</b> .....	Appendix 2 - Page 127
Methamidophos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 127
Methamidophos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 128
Methamidophos Table 3. - Benchmark Dose Calculations for RBC Cholinesterase Measurements Used to Calculate the Oral POD .....	Appendix 2 - Page 130
Methamidophos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 131
Methamidophos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 132
Methamidophos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 133
Methamidophos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 134
Methamidophos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 136
Methamidophos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 138
Methamidophos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 140
Methamidophos Figure 8. - Results of Dose-Response Analysis: Dose-Response Curves for Dermal Route of Exposure .....	Appendix 2 - Page 142
Methamidophos Figure 9. - Results of Dose-Response Analysis: Dose-Response Curves for Inhalation Route of Exposure .....	Appendix 2 - Page 143

<b>Methidathion</b> .....	Appendix 2 - Page 144
Methidathion Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 144
Methidathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 145
Methidathion Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 146
Methidathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 147
Methidathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 149
Methidathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 151
Methidathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 152
Methidathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 153
Methidathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 154
 <b>Methyl Parathion</b> .....	Appendix 2 - Page 155
Methyl Parathion Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 155
Methyl Parathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 156
Methyl Parathion Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 158
Methyl Parathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 159
Methyl Parathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 160
Methyl Parathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 161
Methyl Parathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 162
Methyl Parathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 163
Methyl Parathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 164
 <b>Mevinphos</b> .....	Appendix 2 - Page 165
Mevinphos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 165
Mevinphos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 166
Mevinphos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 167
Mevinphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 168
Mevinphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 170
Mevinphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 172
Mevinphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 173
Mevinphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 174
Mevinphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 175

<b>Naled</b> .....	Appendix 2 - Page 176
Naled Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 176
Naled Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 177
Naled Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 178
Naled Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 179
Naled Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 180
Naled Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 181
Naled Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 182
Naled Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 183
Naled Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 184
 <b>Oxydemetonmethyl</b> .....	Appendix 2 - Page 185
Oxydemetonmethyl Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 185
Oxydemetonmethyl Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 186
Oxydemetonmethyl Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 189
Oxydemetonmethyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 190
Oxydemetonmethyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 191
Oxydemetonmethyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 192
Oxydemetonmethyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 193
Oxydemetonmethyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 195
Oxydemetonmethyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 196
 <b>Phorate</b> .....	Appendix 2 - Page 198
Phorate Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 198
Phorate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 199
Phorate Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 200
Phorate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 201
Phorate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 202
Phorate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 203
Phorate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 204
Phorate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 205
Phorate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 206
 <b>Phosalone</b> .....	Appendix 2 - Page 207

Phosalone Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 207
Phosalone Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 208
Phosalone Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 209
Phosalone Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 210
Phosalone Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 211
Phosalone Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 212
Phosalone Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 213
Phosalone Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 214
Phosalone Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 215
 <b>Phosmet</b> .....	Appendix 2 - Page 216
Phosmet Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 216
Phosmet Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 217
Phosmet Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 218
Phosmet Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 219
Phosmet Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 220
Phosmet Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 221
Phosmet Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 222
Phosmet Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 223
Phosmet Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Reponse Curves for Oral Route of Exposure .....	Appendix 2 - Page 224
 <b>Pirimiphos Methyl</b> .....	Appendix 2 - Page 225
Pirimiphos Methyl Table 1. -Toxicology Profile Table .....	Appendix 2 - Page 225
Pirimiphos Methyl Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 226
Pirimiphos Methyl Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 228
Pirimiphos Methyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 229
Pirimiphos Methyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 230
Pirimiphos Methyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 231
Pirimiphos Methyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 233
Pirimiphos Methyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 235
Pirimiphos Methyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 237
 <b>Terbufos</b> .....	Appendix 2 - Page 239
Terbufos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 239

<b>Terbufos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure</b>	Appendix 2 - Page 240
Terbufos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 242
Terbufos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 243
Terbufos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 244
Terbufos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 245
Terbufos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 247
Terbufos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 249
Terbufos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 251
 <b>Tetrachlorvinphos</b> .....	Appendix 2 - Page 253
Tetrachlorvinphos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 253
Tetrachlorvinphos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 254
Tetrachlorvinphos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 255
Tetrachlorvinphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 256
Tetrachlorvinphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 257
Tetrachlorvinphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 258
Tetrachlorvinphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 259
Tetrachlorvinphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 260
Tetrachlorvinphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 261
 <b>Tribufos</b> .....	Appendix 2 - Page 262
Tribufos Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 262
Tribufos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 263
Tribufos Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 264
Tribufos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 265
Tribufos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 266
Tribufos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 267
Tribufos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 268
Tribufos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 269
Tribufos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 270
 <b>Trichlorfon</b> .....	Appendix 2 - Page 271

Trichlorfon Table 1. - Toxicology Profile Table .....	Appendix 2 - Page 271
Trichlorfon Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure .....	Appendix 2 - Page 272
Trichlorfon Figure 1. - Potency Versus Duration of Exposure Graphs .....	Appendix 2 - Page 273
Trichlorfon Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 274
Trichlorfon Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 275
Trichlorfon Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 276
Trichlorfon Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 277
Trichlorfon Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 278
Trichlorfon Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure .....	Appendix 2 - Page 279


## **Abbreviations**

<b>A</b>	Estimate of A (background cholinesterase activity)
<b>B</b>	Estimate of B (y-assymptote)
<b>BMD<sub>10</sub></b>	Benchmark dose with 10% reduction in cholinesterase activity compared to the background
<b>BMDL</b>	Lower 95% confidence limit on the BMD <sub>10</sub>
<b>cheI</b>	Cholinesterase activity (usually in international units)
<b>CL</b>	Confidence limit
<b>D</b>	Number of days on study
<b>Duplicate</b>	Duplicate animals (i.e., satellite group, recovery animals, etc)
<b>Duplicatewhole</b>	Whole brain from duplicate animals
<b>F</b>	Female
<b>GOF</b>	Model goodness-of-fit
<b>m</b>	Estimate of absolute potency for a single cholinesterase measurement.
<b>M</b>	Male
<b>main</b>	Main study animals
<b>MRID #</b>	MRID study identification number
<b>NA</b>	Not available
<b>RBC</b>	Red blood cells
<b>whole</b>	Whole brain from the main study animals

## Key to Figures in Appendix 2

### Graphs of Potency versus Duration of Exposure

<b>Y-axis</b>	m — Absolute potency estimates for each single cholinesterase measurement
<b>X-axis</b>	Time (number of days)
<b>Error bars</b>	95% confidence intervals on absolute potency estimates
<b>Solid vertical line</b>	Result of regression for duration of exposure and absolute potency (i.e., rough estimate of time to steady state)
<b>Solid horizontal line</b>	Average absolute potency
<b>Dotted horizontal lines</b>	95% confidence intervals on average absolute potency



## Dose-Response Curves

**Y-axis**

Cholinesterase measurements (usually in international units)

**X-axis**

Dose (mg/kg/day)

**Title**


MRID number followed by Number of days on Study followed by - Type of animals (i.e., main, duplicate, satellite) or brain section (i.e, whole, hippocampus, etc.)

**Error bars**

Standard deviations on cholinesterase measurements

**Solid vertical lines**

BMD<sub>10</sub> and BMDL



**Acephate****Acephate Table 1. - Toxicology Profile Table**

ACEPHATE						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
40504819	82-1 (870.3100)	90-day feeding- rat (Special ChE inhibition study)	006680 012544 14258	0/0, 0.15/0.12, 0.36/0.28, 0.76/0.58, 11.48/8.90 mg/kg/day (females/males)	Nonguideline	Rat/ Sprague Dawley
45134301	82-2 (870-3200)	21-Day dermal toxicity study-rat (2000)	14210 41528	0, 20, 30, 40, 50 mg/kg/day	Nonguideline	Rat/ Sprague Dawley
45134302	82-4 (870.3465)	Subchronic Inhalation Study (2000)	14223 41528	0, 0.001064, 0.003123, 0.005550 mg/L	Nonguideline	Rat/ Sprague Dawley
44541101	82-2 (870.3200)	21-day dermal-rat	13396	0, 12, 60, 300 mg/kg/day	Guideline	Rat/ Sprague Dawley
40504818	82-4 (70.3465)	4-week inhalation- rat	12544	0 (air), 1.05, 10.8, 93.6 mg/m <sup>3</sup>	Guideline	Rat/ Fischer 344
40645903	82-4 (80.3465)	4-week inhalation- rat	12544	0 (air), 0.187, 0.507 mg/m <sup>3</sup>	Guideline	Rat/ Fischer 344
00084017	83-5 (70.4300)	1-year chronic feeding/ carcinogenicity study in rats	004951 012544	0, 0.25, 2.50, 35 mg/kg/day (males and females)	Guideline	Rat/ Sprague Dawley
44203304	82-7 (870.6200)	Subchronic neurotoxicity - rats	12416	0/0, 0.41/0.33, 3.95/3.31, 58.27/48.63 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

**Acephate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

ACEPHATE																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	40504819	28D -whole	11.0353177	0	0.235	0.0357	3	2	0.272	0.357	0.469	0.261	0.289	0.319			
			63D - whole	11.9297238	0	0.292	0.0286	3	2									
			91D -whole	12.1515516	5.5574678	0.438	0.0904	5	0									
		00084017	49D-whole	13.5137751	2.400201	0.298	0.347	4	0	0.251	0.279	0.311						
			133D-whole	12.7183242	3.5002725	0.272	0.108	4	0									
			364D-whole	11.8528524	3.4986689	0.248	0.863	4	0									
			637D-whole	11.1111668	3.6982637	0.385	0.724	4	0									
			819D-whole	10.5814594	3.3005802	0.296	0.359	4	0									
	M	40504819	28D -whole	11.0001047	5.7158902	0.465	0.196	5	0	0.417	0.51	0.624	0.274	0.391	0.557			
			63D - whole	11.9918979	6.1316902	0.598	0.84	5	0									
			91D -whole	11.8696972	5.6924649	0.445	0.729	5	0									
		00084017	49D-whole	15.2376661	3.5965661	0.229	0.373	4	0	0.264	0.305	0.353						
			133D-whole	12.1239515	3.7993466	0.273	0.924	4	0									
			364D-whole	11.669167	3.602002	0.339	0.167	4	0									
			637D-whole	11.148995	2.9985647	0.371	0.219	4	0									
			819D-whole	10.47225	3.101021	0.313	0.262	4	0									
RBC	F	44203304	21D-main	2822.376	0	0.008	0.32	4	0	0.00705	0.00885	0.0111	0.00906	0.0216	0.0517			
			49D-main	3232.036	0	0.01	0.634	4	0									
			91D-main	3123.876	0	0.005	0.512	4	0									
		40504819	28D-main	632.693	0	2E-04	0.0032	3	2	0.0376	0.0546	0.0795						
			63D-main	746.2878879	0	0.05	0.303	5	0									
			91D-main	694.694368	382.8456734	0.341	0.9	5	0									
		00084017	42D-main	3246.227205	0	0.12	0.764	3	1	0.0121	0.0218	0.0392						
			49D-main	2903.036	0	0.017	0.152	4	0									
			133D-main	2680.777034	0	0.017	0.186	4	0									
			196D-main	2366.784707	867.808812	0.11	0.539	4	0									
			364D-main	2804.126	0	0.013	0.746	4	0									
			546D-main	2592.275	1325.871	0.023	0.321	4	0									
			637D-main	2616.437	0	0.013	0.323	4	0									
			728D-main	4477.24	0	0.01	0.344	4	0									
			819D-main	2240.305	0	0.016	0.0599	4	0									


Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
RBC (con't)	M	44203304	21D-main	3510.601	1938.046	0.051	0.0901	4	0	0.00777	0.00913	0.0107	0.0094	0.0207	0.0455			
			49D-main	3448.664	0	0.009	0.491	4	0									
			91D-main	3466.4	0	0.009	0.371	4	0									
		40504819	28D-main	537.7864643	212.4274688	0.207	0.682	5	0	0.0313	0.044	0.0619						
			63D-main	634.0131743	0	0.049	0.969	5	0									
			91D-main	864.8536663	0	0.035	0.708	5	0									
		00084017	42D-main	3069.669	0	0.014	0.339	4	0	0.0113	0.0236	0.0494						
			49D-main	3538.519837	1998.650504	0.252	0.735	4	0									
			133D-main	2916.833	0	0.017	0.293	4	0									
			196D-main	2366.329	640.4559	0.068	0.675	4	0									
			364D-main	2892.898	439.3582	0.021	0.08	4	0									
			546D-main	2364.556	0	0.012	0.208	4	0									
			637D-main	3098.376	0	0.01	0.523	4	0									
			728D-main	3975.846	0	0.008	0.24	4	0									
			819D-main	2391.146607	0	0.135	0.549	3	1									
			42D-main	3181.123022	899.9722568	0.292	0.924	4	0	0.0784	0.141	0.255	0.092	0.144	0.225			
Plasma	F	00084017	49D-main	2868.261136	1000.372831	0.257	0.482	4	0									
			133D-main	3022.437313	1260.982722	0.109	0.878	4	0									
			196D-main	3373.551456	1287.826417	0.148	0.0998	4	0									
			364D-main	3127.19883	1282.821042	0.134	0.797	4	0									
			546D-main	2775.446318	1097.502203	0.194	0.0704	4	0									
			637D-main	2780.546	0	0.022	0.81	4	0									
			728D-main	3136.419184	1596.751804	0.174	0.664	4	0									
			819D-main	2042.728311	900.1925822	0.263	0.473	4	0									
		44203304	21D-main	2798.756459	782.624646	0.179	0.31	4	0	0.074	0.147	0.293						
			49D-main	3394.839	905.7005	0.093	0.896	4	0									
			91D-main	3689.265	935.4743	0.045	0.394	4	0									
Plasma	M	00084017	42D-main	1037.65	0	0.004	0.841	4	0	0.00723	0.0141	0.0275	0.0092	0.0447	0.217			
			49D-main	1555.208	0	0.013	0.311	4	0									
			133D-main	1411.781	0	0.01	0.92	4	0									
			196D-main	1110.818	0	0.01	0.118	4	0									
			364D-main	1306.554	0	0.005	0.12	4	0									
			546D-main	1455.354714	590.3266568	0.129	0.309	4	0									
			637D-main	1627.913	0	0.009	0.059	4	0									
			728D-main	1750.228	0	0.011	0.424	4	0									
			819D-main	1427.143163	0	0.136	0.0327	3	1									
		44203304	21D-main	734.4147177	318.9359948	0.175	0.895	4	0	0.0781	0.138	0.244						
			49D-main	639.4006757	268.2689853	0.057	0.79	4	0									
			91D-main	801.4311193	323.8008839	0.098	0.0773	4	0									

# ACEPHATE

Acephate Figure 1. - Potency Versus Duration of Exposure Graphs


BRAIN

F





RBC

M




PLASMA




**Acephate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


ACEPHATE




# ACEPHATE



**Acephate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# ACEPHATE




**Acephate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


ACEPHATE




**Acephate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



**Acephate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



**Acephate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



**Azinphos Methyl****Azinphos Methyl Table 1. - Toxicology Profile Table**

Azinphos Methyl						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/Nonguideline	Species/Strain
43826601	82-1 ( 870.3100)	Subchronic oral (rat)	011898	0/0, 1.05/0.91, 3.23/2.81, 6.99/7.87 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
41119901	83-5 (870.4300)	Chronic/carcinogenicity oral–2 years (rat)	008300	0/0, 0.31/0.25, 0.96/0.75, 3.11/2.33 mg/kg/day (females/males)	Guideline	Rat/ Wistar


**Azinphos Methyl Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	41119901	360D-whole	1.5937	0	0.15	3.6E-09	3	1	0.143	0.214	0.32	0.244	0.274	0.307			
			720D-whole	1.3234	0	0.27	0.00047	4	1									
		43826601	88D-whole	15.738	0	0.28	0.00262	4	0	0.248	0.28	0.316						
	M	41119901	360D-whole	1.8013	0	0.02	6.7E-16	4	0	0.0191	0.0889	0.413	0.209	0.219	0.23			
			720D-whole	1.4003	0	0.21	5.6E-11	4	0									
		43826601	87D-whole	16.198	0	0.22	0.00822	4	0	0.209	0.219	0.23						
RBC	F	41119901	30D-main	2729.5	0	0.16	0.00025	3	1	0.153	0.187	0.229	0.148	0.349	0.821			
			90D-main	2662.5	0	0.12	3.5E-13	4	0									
			180D-main	2775	0	0.19	<2E-16	3	1									
			360D-main	3075.6	0	0.24	2E-09	3	1									
			540D-main	2958.2	0	0.24	0.136	3	1									
			720D-main	3000.8	0	0.19	0.0004	3	1									
		43826601	25D-main	1353	0	0.65	0.095	3	1	0.584	0.643	0.708						
			88D-main	1427.2	24.243	0.49	0.922	4	0									
	M	41119901	30D-main	2657.3	0	0.25	0.0437	3	1	0.196	0.234	0.279	0.199	0.351	0.619			
			90D-main	2987.9	0	0.19	0.00026	3	1									
			180D-main	2779	0	0.15	0.619	3	1									
			360D-main	3143.6	0	0.3	1.1E-06	3	1									
			540D-main	2702.5	0	0.25	0.176	3	1									
			720D-main	2999.2	0	0.28	<2E-16	3	1									
		43826601	24D-main	1151.1	0	0.48	0.301	4	0	0.423	0.532	0.668						
Plasma	F	41119901	30D-main	1119.4	381.8	0.62	0.965	4	0	0.342	0.461	0.623	0.228	0.335	0.49			
			90D-main	1962.4	484.48	0.65	0.659	4	0									
			180D-main	2150.5	90.01	0.38	0.536	4	0									
			360D-main	2351.3	500.91	0.63	0.31	4	0									
			540D-main	2276.2	0	0.41	0.0101	3	1									
			720D-main	2237.2	0	0.24	0.0168	3	1									
		43826601	25D-main	1762.1	0	0.27	0.0972	4	0	0.244	0.263	0.283						
			88D-main	2554.3	0	0.24	0.403	4	0									
	M	41119901	30D-main	409.91	0	0.05	0.00833	3	1	0.0706	0.137	0.265	0.14	0.222	0.35			
			90D-main	489.36	0	0.22	4.8E-10	4	0									
			180D-main	554.06	0	0.04	0.00097	3	1									
			360D-main	726.86	0	0.07	0.0215	3	1									
			540D-main	726.86	0	0.07	0.0492	3	1									
			720D-main	911.41	0	0.33	0.0171	4	0									
		43826601	24D-main	564.39	40.154	0.22	0.325	4	0	0.196	0.285	0.415						
			87D-main	599.02	137.5	0.3	0.553	4	0									


# AZINPHOS METHYL

Azinphos Methyl Figure 1. - Potency Versus Duration of Exposure Graphs


BRAIN





RBC




PLASMA




M




## Azinphos Methyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




## Azinphos Methyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




## Azinphos Methyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




## Azinphos Methyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Azinphos Methyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Azinphos Methyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



**Bensulide****Bensulide Table 1. - Toxicology Profile Table**

Bensulide						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43919601	82-1 (870.3100)	13-Week Subchronic Dietary Toxicity Study in Rats	12289	0/0, 5/5, 15/15, 45/46, or 100/110 mg/kg/day (females/males)	Guideline	Rats/ Sprague Dawley
44161101	83-5 (870.4300)	Combined Chronic Toxicity and Carcinogenicity Study in Rats	12289	0/0, 1/1, 15.30/15.10, 61.30/60.10 mg/kg/day (females/males)	Guideline	Rats/ Sprague Dawley
44801101 44809401	82-2 (870.3200)	Special 21-Day Dermal Toxicity in Rats	013532	0, 30, 50, 500 mgk/kg/day	Nonguideline	Rats/ CD


**Bensulide Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Bensulide																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	43919601	91D-whole	20.18	0	0.008	0.419	5	0	0.00653	0.00845	0.0109	0.00697	0.00798	0.00914			
		44161101	175D-whole	13.5	0	0.008	0.015	4	0	0.00666	0.00781	0.00916						
			357D-whole	13.77	0	0.008	0.216	4	0									
			539D-whole	12.38	0.905	0.006	0.906	4	0									
			721D-whole	10.58	0	0.005	0.007	4	0									
	M	43919601	91D-duplicate	21.34	12.227	0.035	0.677	4	0	0.0117	0.0348	0.103	0.0117	0.0348	0.103			
		44161101	91D-whole	20.73	0	0.004	0.097	5	0	0.00304	0.00428	0.00603	0.00338	0.0043	0.00546			
			175D-whole	13.75	7.1969	0.01	0.805	4	0	0.00309	0.00431	0.00603						
			357D-whole	13.43	0	0.004	0.432	4	0									
			721D-whole	10.73	0	0.005	0.236	4	0									
RBC	F	43919601	91D-main	733	0	0.011	0.88	5	0	0.00944	0.011	0.0129	0.00974	0.0113	0.0132			
		44161101	175D-main	1308	437.26	0.032	0.492	4	0	0.0101	0.0216	0.046						
			357D-main	1461	184.08	0.038	0.595	4	0									
			539D-main	1094	284.14	0.029	0.135	4	0									
			721D-main	1062	0	0.009	0.903	4	0									
Plasma	F	43919601	91D-main	2334	210.06	0.057	0.338	5	0	0.0496	0.0567	0.0648	0.0514	0.0721	0.101			
		44161101	175D-main	2878	334.05	0.114	0.172	4	0	0.0794	0.0924	0.107						
			357D-main	2695	190.97	0.098	0.724	4	0									
			539D-main	2467	280.99	0.091	0.087	4	0									
			721D-main	2372	237.77	0.066	0.183	4	0									
	M	43919601	91D-main	518.2	188.86	0.042	0.7	5	0	0.0297	0.0421	0.0595	0.0368	0.0638	0.111			
		44161101	175D-main	587.1	242.75	0.054	0.221	4	0	0.0728	0.0932	0.119						
			357D-main	831.5	281.18	0.091	0.083	4	0									
			539D-main	950.6	307.75	0.115	0.656	4	0									
			721D-main	1087	267.67	0.087	0.863	4	0									
	M	43919601	91D-main	500.3	167.03	0.026	0.138	5	0	0.0112	0.0257	0.0588	0.0151	0.0257	0.0438			
		44161101	175D-main	1011	476.66	0.055	0.375	4	0	0.0129	0.0258	0.0516						
			357D-main	1446	581.85	0.033	0.083	4	0									
			539D-main	1012	405.6	0.022	0.973	4	0									
			721D-main	1133	0	0.013	0.457	4	0									


# BENSULIDE

**Bensulide Figure 1. - Potency Versus Duration of Exposure Graphs**


BRAIN





RBC





PLASMA



M




**Bensulide Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

**Bensulide Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


# BENSULIDE

Bensulide Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# BENSULIDE

Bensulide Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# BENSULIDE

Bensulide Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# BENSULIDE

Bensulide Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Chlorpyrifos

### Chlorpyrifos Table 1. - Toxicology Profile Table

Chlorpyrifos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
40436406	82-1 (870.3100)	Subchronic Feeding in Rats (90 days)	006851 007302 013240	0/0, 0.05/0.04, 1.00/0.90, 23.40/19.40 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
40952801	82-1 (870.3100)	Subchronic Feeding in Rats (90 days)	007102	0, 0.10, 1.00, 5.00, 15.00 mg/kg/day	Guideline	Rat/ CDF Fischer 344
42172802	83-5 (870.4300)	Chronic Feeding/Carcinogenicity Study in F344 rats (2 yrs)	009733 010605 013240	0/0, 0.01/0.01, 0.37/0.33, 7.61/6.77 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
40952802	83-5 (870.4300)	Chronic Feeding/Carcinogenicity Study in F344 rats (2 yrs)	007107 013240	0, 0.05, 0.10, 1, 10 mg/kg/day	Guideline	Rat/ Fischer 344

**Chlorpyrifos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Chlorpyrifos																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	40952801	91D-whole	11.88	0	0.01	0.789	3	2	0.000339	0.00976	0.281	0.0714	0.111	0.172			
		40952802	360D-whole	11.76	0	0.048	0.0814	4	1	0.0796	0.0854	0.0916						
		42172802	720D-whole	9.003	0	0.086	0.604	5	0									
		40952801	350D-whole	5.166	0	0.184	0.0493	4	0	0.132	0.161	0.198						
		42172802	728D-whole	3.706	0	0.137	0.327	4	0									
	M	40952801	90D-whole	11.33	0	0.023	0.61	3	2	0.00721	0.0227	0.0717	0.027	0.11	0.448			
		40952802	360D-whole	11.12	0	0.71	0.231	3	2	0.0522	0.228	0.992						
		42172802	720D-whole	9.044	0	0.084	0.00375	5	0									
		40952801	350D-whole	6.068	2.279	1.207	0.844	4	0	0.0741	0.337	1.53						
		42172802	728D-whole	3.204	0	0.13	0.0496	4	0									
RBC	F	40952801	44D-main	1836	0	0.437	0.413	3	2	0.338	0.707	1.48	0.0153	0.0894	0.52			
		40952802	91D-main	1879	902.7	1.286	0.64	5	0									
		40952802	180D-main	1748	0	0.014	0.796	5	0									
		42172802	360D-main	1891	0	0.049	0.22	5	0	0.0154	0.0504	0.165						
		40952801	540D-main	2000	0	0.306	0.339	4	1									
		42172802	720D-main	2086	0	0.019	0.133	5	0									
		40952801	350D-main	2402	2119	0.421	0.554	4	0	0.0105	0.0196	0.0365						
	M	40952802	546D-main	2132	0	0.014	0.0383	4	0									
		42172802	728D-main	2684	0	0.031	0.253	4	0									
		40952801	43D-main	2096	0	0.397	0.949	3	2	0.0972	0.223	0.512	0.0511	0.102	0.206			
		40952802	90D-main	1412	0	0.119	0.288	4	1									
		40952802	180D-main	2467	0	0.281	0.207	4	1	0.0375	0.117	0.363						
		42172802	360D-main	1908	0	0.041	0.305	5	0									
		40952801	540D-main	2035	0	0.448	0.447	4	1									
		42172802	720D-main	1565	0	0.033	0.223	5	0	0.0424	0.0589	0.0816						
		40952801	350D-main	2811	0	0.055	0.0483	4	0									
		42172802	546D-main	2276	0	0.075	0.232	4	0									
Did not converge to exponential function																		


# CHLORPYRIFOS

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Plasma	F	40436406	84D-main	3694	0	2.515	0.0109	3	1	2.32	2.52	2.73	1.65	1.94	2.28			
		0952801	44D-main	2980	0	1.71	0.924	3	2	1.64	1.71	1.78						
			91D-main	3431	0	1.708	0.246	3	2									
		40952802	180D-main	3777	619.6	1.559	0.644	5	0	1.39	1.71	2.12						
			360D-main	4490	199.8	2.435	0.142	5	0									
			540D-main	3983	490.1	1.609	0.376	5	0									
			720D-main	2991	509.6	1.378	0.453	5	0									
			42172802	98D-main	3741	716.1	2.042	0.083	4	0	1.69	1.86	2.04					
				224D-main	3821	573.8	2.122	0.661	4	0								
				315D-main	4238	326.6	1.937	0.39	4	0								
				350D-main	4072	82.33	1.892	0.613	4	0								
				546D-main	4001	112.7	1.741	0.557	4	0								
				728D-main	3582	158.4	1.194	0.519	4	0								
	M	40436406	84D-main	592.2	0	0.401	0.0015	3	1	0.284	0.401	0.565	0.467	0.678	0.986			
		40952801	43D-main	631.6	0	0.716	0.12	3	2	0.691	0.787	0.898						
			90D-main	633.3	0	0.865	0.511	3	2									
		40952802	180D-main	713.7	0	0.484	0.874	4	1	0.698	1.17	1.97						
			360D-main	943.5	119.8	1.747	0.0953	5	0									
			540D-main	1433	331.1	1.686	0.524	5	0									
			720D-main	1721	350.3	1.345	0.847	5	0									
		42172802	98D-main	811.4	328.5	0.816	0.613	4	0	0.33	0.601	1.1						
			224D-main	1014	0	0.145	0.313	4	0									
			315D-main	993.7	148.2	0.743	0.409	4	0									
			350D-main	995.1	52	0.57	0.397	4	0									
			546D-main	1404	94.17	1.082	0.541	4	0									
			728D-main	1711	87.12	1.082	0.727	4	0									


# CHLORPYRIFOS

**Chlorpyrifos Figure 1. - Potency Versus Duration of Exposure Graphs**





BRAIN



RBC




PLASMA




# CHLORPYRIFOS

**Chlorpyrifos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# CHLORPYRIFOS

**Chlorpyrifos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# CHLORPYRIFOS

Chlorpyrifos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# CHLORPYRIFOS

Chlorpyrifos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# CHLORPYRIFOS

Chlorpyrifos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# CHLORPYRIFOS

Chlorpyrifos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



**Diazinon****Diazinon Table 1. - Toxicology Profile Table**

Diazinon						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41886301	82-1 (870.3100)	Special Subchronic Feeding Study-- 6 weeks (1991)  Supplementary	009372 012219	0/0, 0.20/0.18, 0.46/0.45, 1.98/1.85, 19.73/18.06, 97.77/90.78, 301.98/272.67 mg/kg/day (female/male)	Nonguideline	Rat/ Sprague Dawley
40815003	82-1 (870.3100)	90-Day Subchronic Feeding Study Rat  Supplementary	007041 007553 012219	0/0, 0.04/0.03, 0.40/0.30, 19/15, 212/168 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
43543902	82-7 (870.6200)	Subchronic Neurotoxicity Rat (1994)	011873	0, 0.3, 30, 300 or 3000 ppm 0/0, 0.02/0.02, 2.00/1.78, 20/18.20, 217/187 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
41942002	83-1 (870.4100)	One-Year Chronic Toxicity in Rat (1991)  Acceptable	010331 012219	0, 0.005/0.004, 0.07/0.06, 6/5, or 12/10 mg/kg/day (males/females)	Guideline	Rat/ Sprague Dawley
43543901	82-7 (870.6200)	Special ChE Inhibition Study--28 days  Supplementary	011873	0/0, 0.02/0.02, 2.4/2.3, 23/23, and 210/213 mg/kg/day (females/males)	Nonguideline	Rat/ Sprague Dawley

**Diazinon Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Diazinon																						
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency							
Brain	F	40815003	87D-whole	3146	0	0.0281	0.155	4	1	0.0272	0.0281	0.0291	0.00542	0.0188	0.0656							
		41886301	42D-whole	65.78	0	0.0042	0.046	7	0	0.0039	0.00418	0.00447										
		41942002	370D-whole	2610	0	0.0558	0.0008	4	1	0.0547	0.0568	0.0591										
			684D-whole	2872	0	0.0571	0.0126	5	0													
	M	40815003	87D-whole	3101	0	0.0043	5E-07	5	0	0.0041	0.00425	0.00438	0.000687	0.00341	0.0169							
		41886301	42D-whole	65.8	0	0.0006	0.71	7	0	0.0005	0.000601	0.000794										
		41942002	370D-whole	2802	0	0.0084	0.0011	5	0	0.0059	0.0216	0.0784										
			684D-whole	2782	0	0.054	0.681	5	0													
RBC	F	40815003	87D-main	2277	0	0.4383	0.021	3	2	0.4	0.438	0.481	0.103	0.269	0.703							
		41886301	28D-main	3908	0	0.0176	0.969	6	1	0.0146	0.0323	0.0715										
			42D-main	5093	537.4	0.0556	0.0764	7	0													
		41942002	88D-main	3455	0	0.6886	0.0344	3	2	0.0693	0.22	0.699										
			181D-main	3470	0	0.7208	0.656	3	2													
			356D-main	3320	0	0.0437	5E-05	4	1													
			552D-main	3435	0	0.5553	6E-05	3	2													
			684D-main	3320	0	0.0468	0.0673	4	1													
		43543901	28D-main	1386	200	0.4741	0.423	5	0	0.244	0.474	0.92										
	43543902		28D-main	1383	230	0.5694	0.589	5	0	0.532	0.74	1.03										
			56D-main	1629	241.9	0.6085	0.131	5	0													
			91D-main	1499	326	1.0358	0.456	5	0													
		40815003	87D-main	2125	0	0.022	0.0011	4	1	0.0206	0.022	0.0236	0.036	0.145	0.585							
	M	41886301	28D-main	5137	0	0.0444	0.786	5	2	0.0407	0.0439	0.0473										
			42D-main	4618	0	0.0433	0.0492	5	2													
		41942002	88D-main	3016	0	0.0359	0.575	4	1	0.0257	0.0811	0.256										
			181D-main	3449	0	0.0354	0.005	4	1													
			356D-main	3125	0	0.0397	3E-08	4	1													
			552D-main	3604	0	0.0661	0.389	4	1													
			684D-main	3042	0	1.1665	0.0008	3	2													
	43543901	28D-main	1818	568	0.7973	0.187	5	0	0.435	0.797	1.46											
		28D-main	1672	514.2	0.9743	0.415	5	0	0.645	1.07	1.79											
		56D-main	1834	291.9	0.4624	0.32	5	0														
	43543902	91D-main	1428	224	1.6983	0.596	5	0														

# DIAZINON

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Plasma	F	40815003	87D-main	2362	0	3.8246	0.417	3	2	3.7	3.82	3.95	0.191	0.298	0.463			
		41886301	28D-main	6989	0	0.2136	0.248	4	3									
		41942002	42D-main	9808	0	0.4041	0.531	4	3									
			88D-main	2473	0	10.856	3E-05	3	2	6.99	8.64	10.7						
			181D-main	2750	0	9.7953	4E-05	3	2									
			356D-main	2509	0	9.8266	0.0003	3	2									
			552D-main	2687	0	7.7568	0.0026	3	2									
			684D-main	2318	0	4.368	0.0343	3	2									
		43543901	28D-main	1300	83.01	0.7391	0.0699	5	0				0.569	0.739	0.96			
	43543902		28D-main	1268	0	0.8195	0.207	3	2				0.839	1.07	1.36			
			56D-main	1669	0	1.0711	0.639	3	2									
			91D-main	2262	0	1.3789	0.565	3	2									
	M	40815003	87D-main	419.1	0	1.2296	9E-07	3	2	1.06	1.23	1.42	0.0261	0.0305	0.0355			
		41886301	28D-main	2268	0	0.0309	0.844	5	2									
		41942002	42D-main	2063	0	0.0301	0.748	5	2									
			88D-main	412.2	72.35	6.545	0.0543	5	0	0.169	1.11	7.3						
			181D-main	450.6	0	0.1856	0.002	4	1									
			356D-main	523	0	0.0428	6E-07	4	1									
			552D-main	854.1	0	3.6001	0.873	3	2									
			684D-main	1051	0	9.7792	3E-05	3	2									
		43543901	28D-main	333	0	0.3002	0.697	3	2	0.23	0.3	0.392	0.271	0.37	0.507			
		43543902	28D-main	333.3	0	0.2756	0.511	3	2									
			56D-main	330.3	0	0.3387	0.792	3	2									
			91D-main	354.1	0	0.5187	0.555	3	2									


# DIAZINON

Diazinon Figure 1. - Potency Versus Duration of Exposure Graphs




# DIAZINON

Diazinon Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# DIAZINON

Diazinon Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# DIAZINON

Diazinon Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# DIAZINON

Diazinon Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# DIAZINON

**Diazinon Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



# DIAZINON

Diazinon Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Dichlorvos

### Dichlorvos Table 1. - Toxicology Profile Table


Dichlorvos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41004701	82-1	90-Day Subchronic Toxicity–Rat	007448	0, 0.1, 1.5, 15 mg/kg/day	Guideline	Rat/ Crl:DC(SD)BR
42958101	82-7 (870.6200)	90-Day Neurotoxicity– Rat	011055 012494	0, 0.1, 7.5, 15 mg/kg/day	Guideline	Rat/ Sprague Dawley Crl:CDBR
40299401	83-5 (870.4300)	Chronic Toxicity/ Carcinogenicity–Rats (NTP study)	006017 012494	0, 4, 8 mg/kg/day	Guideline	Rat/ Fischer 344
00057695 00632569	83-5 (870.3320)	Chronic Inhalation Toxicity/Carcinogenicity (Rat)	001466 006860	0, 0.05, 0.5, 5 mg/m <sup>3</sup>	Supplemental	Rat/ Carworth Farm E (CFE)

**Dichlorvos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Dichlorvos															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	41004701	98D-whole	1336.42	0	0.04	0.896	4	0	0.03	0.04	0.06	0.03	0.04	0.06
	M	41004701	98D-whole	1163.59	769.20	0.19	0.570	4	0	2.24E-03	0.19	16.70	2.24E-03	0.19	16.70
RBC	F	4029940	90D-main	1790.18	0	0.10	2.20E-04	3	0	0.09	0.10	0.11	0.07	0.23	0.78
			270D-main	1688.77	0	0.09	7.66E-07	3	0						
			540D-main	1527.32	0	0.10	0.043	3	0						
		41004701	49D-main	1216.99	0	0.16	0.247	3	1	0.13	0.16	0.20	0.07	0.23	0.78
			98D-main	1275.61	0	0.16	0.044	3	1						
	M	4029940	49D-main	750.00	448.84	6.76	0.818	4	0	0.42	3.85	35.30	0.10	0.14	0.21
			91D-main	708.36	452.97	0.36	0.881	4	0						
			270D-main	1743.00	0	0.05	8.44E-07	3	0	0.06	0.10	0.16	0.10	0.14	0.21
		41004701	360D-main	1712.41	0	0.16	2.00E-04	3	0						
			540D-main	1639.69	0	0.09	9.82E-04	3	0						
			720D-main	1414.71	0	0.15	3.63E-04	3	0						
Plasma	F	4029940	49D-main	1191.51	0	0.18	0.935	3	1	0.14	0.18	0.23	0.12	0.18	0.29
			98D-main	1315.03	0	0.17	0.100	3	1						
			45D-main	1684.30	0	0.23	9.64E-07	3	0	0.23	0.25	0.26	0.12	0.18	0.29
		41004701	90D-main	2016.76	0	0.23	9.83E-07	3	0						
			180D-main	2232.54	0	0.22	6.86E-07	3	0						
			270D-main	2902.67	0	0.26	2.58E-07	3	0						
	M	4029940	360D-main	2431.10	0	0.26	2.69E-07	3	0	0.10	0.12	0.15	0.10	0.12	0.14
			540D-main	2050.94	0	0.29	8.74E-07	3	0						
			49D-main	881.82	328.64	0.27	0.287	4	0	0.08	0.26	0.85	0.10	0.12	0.14
		42958101	98D-main	1124.76	439.40	0.11	0.705	4	0						
			21D-main	1502.91	0	0.10	0.030	3	1						
			49D-main	2036.90	0	0.13	0.052	3	1						
	M	4029940	91D-main	2460.76	837.08	0.43	0.072	4	0	0.10	0.12	0.15	0.10	0.12	0.14
			45D-main	374.48	0	0.15	4.50E-05	3	0						
			90D-main	391.19	0	0.09	8.26E-07	3	0						
		41004701	180D-main	447.28	0	0.09	1.64E-06	3	0	0.01	0.09	0.59	0.10	0.12	0.14
			270D-main	683.78	0	0.12	2.90E-07	3	0						
			360D-main	640.69	0	0.15	3.12E-04	3	0						
	42958101	540D-main	655.58	0	0.14	1.18E-04	3	0	0.02	0.08	0.27	0.10	0.12	0.14	
			49D-main	305.28	111.07	0.35	0.320	4	0						
		98D-main	289.04	0	0.02	0.267	4	0							
	41004701	49D-main	390.84	0	0.04	0.185	4	0	0.02	0.08	0.27	0.10	0.12	0.14	
		91D-main	416.00	206.32	0.24	0.940	4	0							


# DICHLORVOS

Dichlorvos Figure 1. - Potency Versus Duration of Exposure Graphs




# DICHLORVOS

Dichlorvos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




Dichlorvos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




Dichlorvos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

DICHLO  
RVO  
S


40299401 45 D - MAIN




40299401 90 D - MAIN




40299401 180 D - MAIN




40299401 270 D - MAIN




40299401 360 D - MAIN




40299401 540 D - MAIN




41004701 49 D - MAIN




41004701 98 D - MAIN




42958101 21 D - MAIN



42958101 49 D - MAIN




42958101 91 D - MAIN




Dichlorvos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

DICHLOROVOS




# DICHLORVOS

Dichlorvos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# DICHLORVOS

Dichlorvos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Dimethoate

**Dimethoate Table 1. - Toxicology Profile Table**

Dimethoate						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43128201	82-7 (870.6200)	90-Day Neurotoxicity--Rat	011164	0/0, 0.08/0.06, 3.78/3.22, 9.88/8.13 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
164177	83-5 (870.4300)	Chronic toxicity/ Carcinogenicity--Rats	006398 008457	0/0, 0.06/0.04, 0.30/0.23, 1.48/1.16, 6.29/4.82 mg/kg/day (females/males)	Guideline	Rat/ Wistar SPF


**Dimethoate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Dimethoate															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	#Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	00164177	728D-whole	0.5074	0.1858	0.69478	0.448	5	0	0.627	0.695	0.769	0.627	0.695	0.769
	M	00164177	728D-whole	0.4711	0	1.06979	0.092	3	2	0.876	1.07	1.31	0.876	1.07	1.31
RBC	F	00164177	28D-main	25.644	0	0.94054	0.462	3	2	0.296	0.656	1.45	0.203	0.392	0.757
			91D-main	27.223	0	0.91887	0.644	3	2						
			182D-main	25.333	0	0.79933	0.006	3	2						
			364D-main	29.091	12.682	3.29323	1E-03	5	0						
			546D-main	16.292	0	0.16436	0.802	5	0						
			728D-main	24.376	0	0.22263	0.229	5	0						
	43128201		21D-main	7296.9	0	0.00116	0.225	4	0	0.124	0.252	0.51			
			49D-main	2202.6	788.99	0.2394	0.314	4	0						
			91D-main	1698.9	664.37	0.32831	0.802	4	0						
	M	00164177	28D-main	23.446	3.3802	0.55675	0.002	5	0	0.301	0.492	0.803	0.278	0.431	0.666
			91D-main	23.718	0	1.10394	3E-05	3	2						
			182D-main	21.242	0	0.32867	4E-05	3	2						
			364D-main	22.004	0	0.30493	0.007	5	0						
			546D-main	15.946	0	0.2103	2E-04	4	1						
			728D-main	28.156	0	0.94336	0.002	3	2						
	43128201		21D-main	6800.6	0	0.00895	0.538	3	1	0.0983	0.258	0.675			
			49D-main	1938.9	0	0.18148	0.076	3	1						
			91D-main	1721.9	830.38	0.82958	0.671	4	0						
Plasma	F	00164177	28D-main	33.781	0	0.12353	0.009	5	0	0.0526	0.0827	0.13	0.0567	0.0759	0.102
			91D-main	46.167	0	0.12883	0.029	5	0						
			182D-main	52.584	0	0.01863	6E-04	4	1						
			364D-main	52.567	0	0.03081	0.035	4	1						
			546D-main	35.44	0	0.07457	4E-05	4	1						
			728D-main	29.124	0	0.07529	0.003	4	1						
	43128201		21D-main	2854.1	0	0.07433	0.288	4	0	0.0488	0.0714	0.104			
			49D-main	2241.1	0	0.07591	0.214	4	0						
			91D-main	2497.7	0	0.05919	0.27	4	0						
	M	00164177	28D-main	9.7775	0	0.16352	0.225	5	0	0.159	0.166	0.173	0.159	0.166	0.173
			91D-main	12.674	1.7228	0.21162	0.206	5	0						
			182D-main	13.505	0	0.06484	3E-04	4	1						
			364D-main	16.35	0	0.16065	0.382	5	0						
			546D-main	16.09	0	0.17781	7E-04	5	0						
			728D-main	16.94	0	0.16097	8E-04	5	0						
	43128201		21D-main	637.55	404.17	0.20278	0.718	4	0	0.151	0.328	0.71			
			49D-main	360.51	127.21	0.13992	0.844	4	0						
			91D-main	370.78	192.6	0.40725	0.562	4	0						


**Dimethoate Figure 1. - Potency Versus Duration of Exposure Graphs**

# DIMETHOATE


BRAIN



RBC




PLASMA




# DIMETHOATE

Dimethoate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



**Dimethoate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


DIMETHOATE




**Dimethoate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

DIMETHOATE


**164177 28 D - MAIN**




**164177 91 D - MAIN**




**164177 182 D - MAIN**




**164177 364 D - MAIN**




**164177 546 D - MAIN**




**164177 728 D - MAIN**




**43128201 21 D - MAIN**



**43128201 49 D - MAIN**




**43128201 91 D - MAIN**




## Dimethoate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

DIMETHOATE


164177 28 D - MAIN




164177 91 D - MAIN




164177 182 D - MAIN




164177 364 D - MAIN




164177 546 D - MAIN




164177 728 D - MAIN




43128201 21 D - MAIN



43128201 49 D - MAIN




43128201 91 D - MAIN




**Dimethoate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

DIMETHOATE


**164177 28 D - MAIN**




**164177 91 D - MAIN**




**164177 182 D - MAIN**




**164177 364 D - MAIN**




**164177 546 D - MAIN**




**164177 728 D - MAIN**




**43128201 21 D - MAIN**



**43128201 49 D - MAIN**




**43128201 91 D - MAIN**




**Dimethoate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

DIMETHOATE


**164177 28 D - MAIN**




**164177 91 D - MAIN**




**164177 182 D - MAIN**




**164177 364 D - MAIN**




**164177 546 D - MAIN**




**164177 728 D - MAIN**




**43128201 21 D - MAIN**



**43128201 49 D - MAIN**



**43128201 91 D - MAIN**



**Disulfoton****Disulfoton Table 1. - Toxicology Profile Table**

Disulfoton						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00162338	82-2 (870.3200)	21-day Dermal Toxicity–Rabbit	005556	0, 0.4, 1.6, 6.5 mg/kg/day	Guideline	Rabbit/ New Zealand
41224301	82-4 (870.3465)	Subchronic Inhalation–Rat	011242	Air and PEG-400:50% ethanol vehicle controls, 0.016/0.018, 0.16/0.16, 1.4/1.4 mg/m <sup>3</sup> (females/males)	Guideline	Rat/ Fischer 344
42977401	82-7 (870.6200)	Subchronic Neurotoxicity–Rat	011456	0/0, 0.07/0.06, 0.31/0.27, 1.30/1.08 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
43058401	Non-guideline study	Special 6-month Cholinesterase–Rat	011249	0/0, 0.02/0.02, 0.03/0.03, 0.07/0.06 mg/kg/day (females/males)	Nonguideline	Rat/ Fischer CDF (F-344) BR
41850002	83-5 (870.4300)	Chronic Toxicity/carcinogenicity–Rat	005029	0/0, 0.08/0.06, 0.26/0.22, 1.25/0.92 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
45239601	82-2 (870.3200)	21-day Dermal Toxicity–Rabbit	014448	0, 0.8, 1, 3 mg/kg/day	Guideline	Rabbit/ New Zealand White (HC:NZW)

**Disulfoton Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Disulfoton																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	41850002	735D-whole	14.4202	2.49333	3.932	0.948	4	0	3.05	3.93	5.07	1.99	2.91	4.24			
		42977401	91D-whole	15.2965	0	3.378	0.00283	3	1	3.19	3.38	3.58						
		43058401	60D-whole	16.4585	0	1.058	0.00374	4	0	1.22	1.71	2.4						
			116D-whole	15.7483	0	2.059	0.888	4	0									
			179D-whole	15.6931	0	2.114	0.084	4	0									
	M	41850002	735D-whole	14.636	2.9005	5.034	0.135	4	0	4.39	5.03	5.77	0.654	1.82	5.06			
		42977401	91D-whole	14.5192	0	1.7	0.0221	3	1	1.51	1.7	1.92						
		43058401	59D-whole	15.7717	0	0.05	0.191	4	0	0.133	0.438	1.44						
			115D-whole	15.5271	0	0.478	0.00437	4	0									
			178D-whole	15.6547	0	0.303	0.0664	4	0									
RBC	F	41850002	98D-main	1717.67	0	4.548	0.000242	3	1	4.04	4.64	5.32	4.43	4.87	5.36			
			189D-main	1728.19	0	4.656	0.000559	3	1									
			371D-main	1615.13	0	4.962	0.00264	3	1									
			553D-main	1640.13	0	5.769	0.00121	3	1									
			735D-main	1566.59	0	3.428	0.0262	3	1									
		42977401	24D-main	1711.86	17.8716	5.138	0.963	4	0	4.87	5.35	5.87	4.43	4.87	5.36			
			87D-main	1534.9	0	5.348	0.00199	3	0									
		43058401	57D-main	1571.12	0	4.548	0.363	4	0	3.9	4.47	5.12	2.94	3.55	4.28			
			113D-main	1525.42	0	4.953	0.666	4	0									
			176D-main	1509.95	0	3.827	0.0951	4	0									
	M	41850002	98D-main	1786.69	500.183	5.428	0.195	4	0	3.34	4.34	5.64	2.94	3.55	4.28			
			189D-main	1910.03	0	2.899	0.00129	3	1									
			371D-main	1900.5	0	3.216	0.129	3	1									
			553D-main	1843.76	0	5.164	0.0188	3	1									
			735D-main	1559.25	304.353	6.02	0.142	4	0									
		42977401	24D-main	1774.01	0	3.597	0.0567	3	0	3.25	3.69	4.18	1.96	2.62	3.5			
			87D-main	1728.58	79.0147	4.645	0.602	4	0									
		43058401	56D-main	1490.14	0	2.724	0.441	4	0	1.96	2.62	3.5	2.71	3.74	5.16			
			112D-main	1437.44	0	1.98	0.14	4	0									
			175D-main	1642.76	0	3.082	3.86E-05	4	0									
Plasma	F	41850002	98D-main	2434.4	118.345	5.833	0.37	4	0	4.9	5.22	5.55	2.71	3.74	5.16			
			189D-main	3304.57	167.352	5.717	0.0743	4	0									
			371D-main	3224.44	0	5.048	0.0479	3	1									
			553D-main	3310.46	0	4.94	0.0143	3	1									
			735D-main	2894.5	124.514	4.976	0.441	4	0									
	42977401	24D-main	1606.95	130.606	3.335	0.402	4	0	3.14	3.54	3.98	1.76	2.51	3.57				
		87D-main	2673.95	70.9379	3.783	0.183	4	0										
		43058401	57D-main	1706.71	1519.16	19.9	0.506	4	0									
			113D-main	2190.91	0	1.891	0.301	4	0									
			176D-main	2683.67	0	2.71	0.752	4	0									


# DISULFOTON

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma (con't)	M	41850002	98D-main	562.713	0	1.121	0.796	4	0	1.08	1.89	3.31	0.997	1.41	2.01
			189D-main	899.626	130.842	1.94	0.176	4	0						
			371D-main	793.35	0	0.78	0.0485	3	1						
			553D-main	1120.82	128.066	2.715	0.585	4	0						
			735D-main	1676.49	70.7145	4.815	0.207	4	0						
		42977401	24D-main	644.876	0	1.084	0.000268	4	0	1.02	1.1	1.18	0.997	1.41	2.01
			87D-main	670.794	66.6236	1.635	0.129	4	0						
		43058401	56D-main	584.792	0	2.633	0.152	3	1	1.1	2.11	4.06	0.997	1.41	2.01
			112D-main	629.363	0	0.108	0.137	4	0						
			175D-main	687.771	0	1.378	0.000942	4	0						


# DISULFOTON

**Disulfoton Figure 1. - Potency Versus Duration of Exposure Graphs**


BRAIN



RBC




PLASMA




# DISULFOTON

Disulfoton Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# DISULFOTON

Disulfoton Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



**Disulfoton Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


DISULFOTON



**Disulfoton Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


DISULFOTON

41850002 98 D - MAIN




Continuous Exponential Model (Decreasing)

41850002 189 D - MAIN




Continuous Exponential Model (Decreasing)

41850002 371 D - MAIN




Continuous Exponential Model (Decreasing)

41850002 553 D - MAIN




Continuous Exponential Model (Decreasing)

41850002 735 D - MAIN




Continuous Exponential Model (Decreasing)

42977401 24 D - MAIN




Continuous Exponential Model (Decreasing)

42977401 87 D - MAIN




Continuous Exponential Model (Decreasing)

43058401 56 D - MAIN




Continuous Exponential Model (Decreasing)

43058401 112 D - MAIN



Continuous Exponential Model (Decreasing)

43058401 175 D - MAIN




Continuous Exponential Model (Decreasing)


## Disulfoton Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

DISULFOTON


41850002 98 D - MAIN




41850002 189 D - MAIN




41850002 371 D - MAIN




41850002 553 D - MAIN




41850002 735 D - MAIN




42977401 24 D - MAIN




42977401 87 D - MAIN




43058401 57 D - MAIN



43058401 113 D - MAIN




43058401 176 D - MAIN



## Disulfoton Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

DISULFOTON



## Fenamiphos

**Fenamiphos Table 1. - Toxicology Profile Table**

Fenamiphos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00154497	82-2 (870.3200)	21-Day Dermal Toxicity–Rabbit	004531 005722	0, 0.5, 2.5, 10 mg/kg/day	Guideline	Rabbit/ New Zealand White
40774809	82-4 (870.3465)	21-Day Inhalation Toxicity–Rat (nose only)	004531 010301 011035	0, 0.03, 0.25, 3.5 Fg/L	Guideline	Rat/ Wistar Albino
00161361	83-5 (870.4300)	Chronic toxicity/Carcinogenicity– Rat	003331 003606 005722	0/0, 0.12/0.10, 0.60/0.46, 3.36/2.45 mg/kg/day (females/males)	Guideline	Rat/ Fischer
44051401	82-7 (870.6200)	Subchronic Neurotoxicity–Rat	012019	0/0, 0.08/0.06, 0.80/0.61, 3.98/3.13 mg/kg/day (females/males)	Guideline	Rat/ Wistar

**Fenamiphos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency	
Brain	F	00161361	763D-whole	12.28	0	0.03	0.893	4	0	0.01	0.03	0.08	0.03	0.0387 (brain-female)	0.05	
		44051401	105D-whole	12.23	0	0.04	0.048	4	0	0.03	0.04	0.05				
	M	00161361	763D-whole	12.95	0	0.05	0.322	4	0	0.03	0.05	0.08	0.03	0.049 (brain-male)	0.08	
		44051401	105D-whole	11.98	0	0.02	0.328	4	0	3.13E-03	0.02	0.14				
	RBC	F	00161361	42D-main	1797.64	325.92	1.23	0.084	4	0	0.69	0.88	1.11	0.60	0.753 (RBC-female)	0.95
				70D-main	1878.24	271.05	0.77	2.21E-04	4	0						
				105D-main	1791.57	0	0.73	2.69E-03	3	1						
				189D-main	1700.35	269.68	1.06	6.70E-03	4	0						
				371D-main	1787.61	0	0.57	0.089	3	1						
				546D-main	1920.13	421.92	1.31	0.997	4	0						
				742D-main	1676.75	412.56	0.51	0.385	4	0						
		44051401	105D-main	28D-main	867.26	0	0.51	0.809	4	0	0.48	0.63	0.83	0.60	0.753 (RBC-female)	0.95
				105D-main	814.11	0	0.77	0.055	4	0						
	M	00161361	00161361	42D-main	1938.57	0	0.68	0.346	4	0	0.35	0.46	0.59	0.44	0.56 (RBC-male)	0.72
				70D-main	1860.06	0	0.30	0.197	3	1						
				105D-main	1879.95	0	0.63	0.911	4	0						
				189D-main	1866.37	0	0.55	0.059	3	1						
				371D-main	1904.47	0	0.32	5.03E-03	3	1						
				742D-main	1673.77	0	0.34	0.685	4	0						
				28D-main	867.28	0	0.69	0.094	4	0						
				105D-main	699.89	0	0.46	0.719	3	1						

# FENAMIPHOS

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency	
Plasma	F	00161361	42D-main	1911.29	213.16	3.66	4.05E-03	4	0	2.85	3.21	3.62	1.91	2.6 (plasma-female)	3.54	
			70D-main	2148.30	0	2.34	5.09E-04	3	1							
			105D-main	2423.51	291.67	3.25	8.87E-03	4	0							
			189D-main	2582.73	221.92	3.66	0.078	4	0							
			371D-main	3180.00	179.98	3.60	Insufficient degrees of freedom to compute a GOF	3	0							
			546D-main	2597.80	151.12	3.42	0.107	4	0							
			742D-main	2097.87	219.51	2.90	0.535	4	0							
			44051401	28D-main	1170.79	150.06	1.88	0.241	4	0	1.71	2.06	2.48			
				105D-main	1634.20	171.40	2.18	0.181	4	0						
	M	00161361	42D-main	759.56	226.51	2.02	0.129	4	0	0.83	1.42	2.44	0.82	1.22 (plasma-male)	1.83	
			70D-main	614.37	145.55	0.61	0.817	4	0							
			105D-main	630.87	262.07	1.23	0.924	4	0							
			371D-main	783.76	157.95	0.88	0.069	4	0							
			546D-main	1042.33	0	0.80	8.38E-04	3	0							
			742D-main	1317.49	320.25	4.98	0.973	4	0							
			44051401	28D-main	422.65	109.71	0.75	0.471	4	0						
				105D-main	492.78	151.79	1.18	0.420	4	0						


# FENAMIPHOS

Fenamiphos Figure 1. - Potency Versus Duration of Exposure Graphs




# FENAMIPHOS

Fenamiphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# FENAMIPHOS

Fenamiphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




Fenamiphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

FENAMIPHOS




## Fenamiphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



Fenamiphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure


FENAMIPHOS

161361 42 D - MAIN




Continuous Exponential Model (Decreasing)

161361 70 D - MAIN




Continuous Exponential Model (Decreasing)

161361 105 D - MAIN




Continuous Exponential Model (Decreasing)

161361 189 D - MAIN




Continuous Exponential Model (Decreasing)

161361 371 D - MAIN




Continuous Exponential Model (Decreasing)

161361 546 D - MAIN




Continuous Exponential Model (Decreasing)

161361 742 D - MAIN




Continuous Exponential Model (Decreasing)

44051401 28 D - MAIN



Continuous Exponential Model (Decreasing)

44051401 105 D - MAIN




Continuous Exponential Model (Decreasing)


## Fenamiphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

FENAMIPHOS


161361 42 D - MAIN




161361 70 D - MAIN




161361 105 D - MAIN




161361 189 D - MAIN




161361 371 D - MAIN




161361 742 D - MAIN



44051401 28 D - MAIN



44051401 105 D - MAIN



**Fosthiazate****Fosthiazate Table 1. - Toxicology Profile Table**

Fosthiazate*						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
44269908	82-7 (870.6200)	90-Day Neurotoxicity Study–Rat	In review	0/0, 0.08/0.07, 0.57/0.56, 2.5/2.4 mg/kg/day (females/males)	In review	Rat/ Charles River CD (SD)
44269905	82-1 (870.3100)	4-Week Preliminary Dietary Toxicity–Rat	In review	0, 0.03, 0.05, 0.25, 0.50, 5, 20 mg/kg/day	In review	Rat/ Charles River CD (remote SD origin)
41347632	82-1 (870.3100)	13-Week Dietary Toxicity	008039	0, 1.07, 10.7, 53.6, 429 ppm 0/0, 0.09/0.08, 0.89/0.77, 4.74/4.12, 41.03/36.37 mg/kg/day females/males	Guideline	Rat/ CD
43559703	83-5 (870.4300)	Combined Chronic Toxicity/Carcinogenicity Study–Rats  Acceptable/Guideline	008039	0/0, 0.05/0.04, 0.50/0.38, 2.45/1.94, 11.69/8.34 mg/kg/day (females/males)	Guideline	Rat/ Charles River CD

\*Not yet registered

**Fosthiazate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Fosthiazate																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	41347632	91D-whole	9.8221	0	0.028	0.634	3	2	8.7E-05	0.028	8.97	0.172	0.276	0.441			
		43559703	371D-whole	10.916	0	0.042	0.543	3	2	0.191	0.199	0.208						
			728D-whole	10.238	0	0.199	9E-09	5	0									
		44269905	28D-whole	10.909	1.495	0.394	0.0875	7	0	0.362	0.394	0.43						
	M	41347632	91D-whole	10.259	1.393	0.079	0.0726	5	0	0.0534	0.0787	0.116	0.0817	0.115	0.163			
		43559703	371D-whole	9.024	1.596	0.516	0.0723	5	0	0.0629	0.255	1.04						
			728D-whole	9.6609	0	0.043	0.527	3	2									
		44269905	28D-whole	12.116	1.182	0.136	0.278	7	0	0.114	0.136	0.163						
RBC	F	41347632	84D-main	2076.5	143.9	0.317	0.109	5	0	0.291	0.317	0.344	0.311	0.432	0.6			
		43559703	84D-main	1860.7	0	0.775	0.437	3	2	0.584	0.673	0.775						
			168D-main	2093.9	140.1	0.668	0.0036	5	0									
		44269905	196D-main	2405.8	0	0.587	4E-11	4	1									
			357D-main	1885.1	0	0.912	0.645	3	2									
		44269908	364D-main	1882.1	184.7	0.731	0.485	5	0									
			532D-main	2508.1	195.8	0.481	0.34	5	0									
			714D-main	2242.1	313.6	0.642	0.0683	5	0									
		44269905	26D-main	2064.3	204.2	0.412	0.0049	7	0	0.377	0.412	0.45						
		44269908	35D-main	133.08	77.85	0.36	0.504	4	0	0.11	0.32	0.93						
			63D-main	146.19	94.02	0.802	0.128	4	0									
			98D-main	137.48	0	0.142	0.151	4	0									
	M	41347632	84D-main	1941.7	0	0.059	0.0451	3	2	0.00571	0.0595	0.62	0.122	0.265	0.579			
		43559703	84D-main	1995.3	339.5	0.796	0.501	5	0	0.531	0.618	0.718						
			168D-main	2569.8	0	0.564	6E-05	4	1									
		44269905	357D-main	2939	0	0.592	0.125	4	1									
			532D-main	3006.9	352.3	0.686	0.473	5	0									
			714D-main	2466.4	288.2	0.463	0.788	5	0									
		44269905	25D-main	2339	213.8	0.377	0.847	7	0	0.353	0.377	0.402						
		44269908	35D-main	133.22	0	0.077	0.0143	4	0	0.0793	0.114	0.162						
			63D-main	139.78	0	0.099	0.224	4	0									
			98D-main	136.53	0	0.165	0.0353	4	0									

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Plasma	F	41347632	84D-main	4111.8	0	0.852	0.0997	3	2	0.671	0.852	1.08	1.03	1.31	1.66			
		43559703	84D-main	3759.1	0	1.846	4E-06	3	2	1.48	1.67	1.89						
			168D-main	5015.9	0	2.104	0.0002	3	2									
			196D-main	4294.9	0	1.482	0.0002	3	2									
			357D-main	4214.7	0	1.974	0.0017	3	2									
			364D-main	4059.4	0	1.577	0.0002	3	2									
			532D-main	4025.1	0	1.265	0.0008	3	2									
			714D-main	3779.9	0	1.521	0.67	3	2									
	44269905	26D-main	2541.4	0	1.334	0.491	5	2	1.07	1.33	1.67	1.21	1.44	1.71				
		44269908	35D-main	1478	205.3	1.25	0.254	4	0									
			63D-main	2041.2	224.5	1.615	0.91	4	0									
			98D-main	2102.7	142	1.351	0.24	4	0									
M	41347632	84D-main	840.51	324.4	0.343	0.113	5	0	0.252	0.343	0.469	0.705	0.847	1.02				
		43559703	84D-main	666.05	301.3	0.674	0.747	5	0									
			168D-main	851.04	370.7	0.827	0.238	5	0									
			357D-main	978.89	313.1	0.994	0.388	5	0									
			532D-main	1332.1	0	0.437	0.0004	3	2									
			714D-main	2084.4	470.4	1.117	0.174	5	0									
	44269905	25D-main	695.51	0	0.121	0.15	6	1	0.102	0.121	0.144	0.243	0.292	0.351				
		44269908	35D-main	519.22	0	0.221	0.533	4	0									
			63D-main	501.87	0	0.31	0.0977	4	0									
			98D-main	471.95	197.1	0.725	0.94	4	0									


# FOSTHIAZATE

Fosthiazate Figure 1. - Potency Versus Duration of Exposure Graphs


BRAIN






RBC



PLASMA




M




# FOSTHIAZATE

Fosthiazate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# FOSTHIAZATE

**Fosthiazate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# FOSTHIAZATE

Fosthiazate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# FOSTHIAZATE

Fosthiazate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# FOSTHIAZATE

Fosthiazate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# FOSTHIAZATE

Fosthiazate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Malathion

**Malathion Table 1. - Toxicology Profile Table**

Malathion						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41054201	82-2 (870.3200)	21-Day Dermal–Rabbit (1988) (Malathion Technical 94% a.i.)	008714 009385 012433	0, 50, 300, 1000 mg/kg/day	Guideline	Rabbit/ New Zealand Albino
43266601	82-4 (870.3465)	13-Week Inhalation– Rat (1994) (Malathion Technical 96.4% a.i.)	012433 011516	0 (air), 0.1, 0.45, 2.01 mg/L	Nonguideline	Rat/ Sprague Dawley
43942901	83-5 (870.4300)	Combined Chronic Toxicity/Carcinogenicity–F344 Rats (1996) (Malathion Technical 97.1% a.i.)	013822 014120 014121	0/0, 5/4 , 35/29, 415/359, 868/739 mg/kg/day (females/males )	Guideline	Rat/ CDF(F-344)CrlBR
43269501	82-7 (870.6200)	Subchronic Neurotoxicity–Rat (Malathion Technical 96.4%)	14120	0/0, 4/4, 395/352, 1575/1486 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley


**Malathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency				
Brain	F	43942901	91D-whole	10.71	0	3.89E-04	0.506	4	1	3.70E-04	4.06E-04	4.45E-04	3.70E-04	4.06E-04	4.45E-04				
			182D-whole	9.82	0	4.15E-04	0.272	4	1										
			364D-whole	9.99	0	3.73E-04	0.685	5	0										
			728D-whole	10.73	0	4.84E-04	0.986	4	1										
	M	43942901	91D-whole	10.81	0	3.80E-04	0.943	4	1	2.17E-04	3.85E-04	6.81E-04	2.17E-04	3.85E-04	6.81E-04				
			182D-whole	9.90	0	2.70E-04	0.491	5	0										
			364D-whole	9.80	0	2.18E-04	0.175	5	0										
			728D-whole	10.72	0	1.03E-03	0.982	4	0										
RBC	F	43269501	21D-main	1020.28	358.85	4.09E-03	0.657	4	0	2.75E-03	3.69E-03	4.94E-03	3.12E-03	4.10E-03	5.39E-03				
			49D-main	889.73	298.97	4.02E-03	0.877	4	0										
			91D-main	1230.41	384.84	3.24E-03	0.893	4	0										
		43942901	91D-main	1304.80	0	7.64E-03	0.033	3	2	3.82E-03	7.88E-03	1.62E-02							
	M		182D-main	1407.39	572.56	3.37E-03	0.716	5	0										
			364D-main	1490.62	747.39	5.87E-03	0.304	5	0										
			728D-main	1380.46	704.68	0.02	0.172	5	0										
	43269501	21D-main	898.38	409.21	8.83E-03	0.612	4	0	3.49E-03	5.28E-03	8.00E-03	2.93E-03	4.24E-03	6.13E-03					
		49D-main	802.24	259.96	6.77E-03	0.978	4	0											
		91D-main	1055.59	388.75	4.22E-03	0.948	4	0											
		43942901	91D-main	1068.75	452.95	7.62E-03	0.062	5	0	1.77E-03	3.03E-03	5.19E-03							
Plasma	F	43269501	182D-main	3386.66	0	1.55E-03	0.244	5	0	5.78E-04	7.18E-04	8.94E-04	6.04E-04	1.14E-03	2.13E-03				
			364D-main	3554.45	0	1.43E-03	0.707	5	0										
			728D-main	3444.33	0	2.45E-03	0.563	5	0										
		43269501	21D-main	340.64	0	4.66E-04	0.437	4	0	3.90E-04	4.62E-04	5.46E-04	4.00E-04	4.72E-04	5.58E-04				
			49D-main	309.40	81.27	8.91E-04	0.983	4	0										
			91D-main	296.10	0	4.49E-04	0.537	4	0										
			43942901	91D-main	631.67	0	1.02E-03	0.342	5	0	4.67E-04	1.68E-03	6.01E-03						
	M	43269501	182D-main	620.25	0	7.14E-04	0.509	4	1										
			364D-main	740.34	0	7.28E-04	0.256	5	0										
			728D-main	1787.82	674.11	0.02	0.463	4	0										


# MALATHION

Malathion Figure 1. - Potency Versus Duration of Exposure Graphs


BRAIN






RBC




PLASMA



M




**Malathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# MALATHION


43269501 21 D - OLFACTORY




43269501 49 D - OLFACTORY




43269501 91 D - OLFACTORY




43942901 91 D - WHOLE




43942901 182 D - WHOLE




43942901 364 D - WHOLE



43942901 728 D - WHOLE




**Malathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# MALATHION


43269501 21 D - OLFACTORY




43269501 49 D - OLFACTORY




43269501 91 D - OLFACTORY




43942901 91 D - WHOLE




43942901 182 D - WHOLE



43942901 364 D - WHOLE




43942901 728 D - WHOLE




# MALATHION

Malathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# MALATHION

Malathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




**Malathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



# MALATHION

Malathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# METHAMIDOPHOS

## Methamidophos

**Methamidophos Table 1. - Toxicology Profile Table**

Methamidophos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
44525301	82-2 (870.3200)	21-Day Dermal–Rat	13394	0, 0.75, 11.2, 36.5 mg/kg/day	Guideline	Rat/ Sprague Dawley
00147935	82-2 (870.3200)	21-Day Dermal–Rabbit	11779	0, 0.5, 5 mg/kg/day	Nonguideline	Rabbit/ NZW
41402401	82-3 (870.3465)	90-Day Subchronic Inhalation–Rat	011550 012826	Air and vehicle [PEG E400:ethanol] controls, 0.0011, 0.0054, 0.0231 mg/L	Guideline	Rat/ Wistar
41867201	82-1 Special ChE study	Subchronic Oral–Rat	008846 012826	0/0, 0.06/0.03, 0.06/0.07, 0.17/0.13, 0.28/0.24 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
43197901	82-7 (870-6200)	Subchronic Neurotoxicity Screening Study in Rats	011530 012826	0/0, 0.07/0.07, 0.90/0.79, 4.94/4.26 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
00148452	83-5 (870.4300)	Combined Chronic/Carcinogenicity–Rat	005313 007124 012514	0, 0.20, 0.60, 1.80, 5.40 mg/kg/day	Guideline	Rat/ Fischer 344

**Methamidophos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Methamidophos																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	00148452	360D-whole	13.64	0	0.96	0.005	3	2	0.88	0.97	1.06	0.90	1.09	1.33			
			720D-whole	12.32	2.84	1.00	0.439	5	0									
		41867201	35D-whole	14.94	0	1.02	0.013	4	1	0.84	0.97	1.11						
			56D-whole	14.20	0	0.85	0.322	4	1									
		43197901	87D-whole	16.64	2.38	1.38	0.431	4	0	1.27	1.38	1.50						
	M	148452	360D-whole	13.89	0	0.88	0.004	3	2	0.82	0.91	1.02	0.95	1.19	1.50			
			720D-whole	11.97	2.46	0.95	0.335	5	0									
		41867201	35D-whole	15.15	0	1.22	0.051	5	0	1.16	1.23	1.31						
			56D-whole	14.48	0	1.24	0.455	5	0									
		43197901	86D-whole	15.79	2.38	1.50	0.351	4	0	1.41	1.50	1.59						
RBC	F	148452	180D-main	1500.85	0	0.95	0.069	3	2	0.94	1.09	1.26	0.70	1.00	1.44			
			360D-main	1524.37	435.25	1.42	0.107	5	0									
			450D-main	1667.25	349.54	1.22	0.769	5	0									
			540D-main	1631.12	0	0.93	0.021	3	2									
			720D-main	1522.76	293.93	0.99	0.646	5	0									
		41867201	28D-main	2676.93	0	0.70	0.842	4	1	0.58	0.68	0.80	0.82	1.23	1.83			
			42D-main	2619.03	0	0.75	0.564	4	1									
			51D-main	2605.15	0	0.56	0.223	4	1									
		43197901	24D-main	1333.30	29.84	1.83	0.820	4	0	1.04	1.52	2.21						
			86D-main	1345.20	58.98	1.44	0.976	4	0									
	M	148452	180D-main	1634.60	0	0.74	0.011	4	1	0.83	0.96	1.11	0.82	1.23	1.83			
			360D-main	1771.17	0	0.90	0.933	3	2									
			450D-main	1866.57	326.79	1.13	0.774	5	0									
			540D-main	1797.88	347.75	1.07	0.109	5	0									
			720D-main	1540.50	363.16	1.04	0.694	5	0									
		41867201	28D-main	2820.64	0	1.20	0.051	5	0	0.77	0.97	1.24						
			42D-main	2720.02	0	1.02	0.809	5	0									
			51D-main	2645.74	0	0.76	0.421	5	0									
		43197901	24D-main	1560.27	308.19	2.78	0.619	4	0	1.55	2.10	2.85						
			86D-main	1538.34	49.68	1.99	0.837	4	0									

# METHAMIDOPHOS

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency	
Plasma	F	148452	180D-main	2273.62	179.51	0.85	0.150	5	0	0.74	0.94	1.20	0.94	1.24	1.64
			360D-main	2722.67	497.02	1.62	0.494	5	0						
			450D-main	2541.99	231.18	0.88	0.041	5	0						
			540D-main	2933.55	92.88	0.76	0.117	5	0						
			720D-main	2531.66	179.15	0.81	0.372	5	0						
		41867201	28D-main	2416.01	1331.31	5.45	0.888	5	0	1.43	3.18	7.06	0.94	1.24	1.64
			42D-main	2080.84	0	1.40	0.011	5	0						
			51D-main	2150.00	0	5.62	4.25E-08	3	2						
	M	148452	24D-main	1622.97	157.87	1.32	0.172	4	0	1.16	1.27	1.39	0.69	0.87	1.10
			86D-main	2368.00	245.38	1.24	0.773	4	0						
			180D-main	560.75	99.11	0.70	0.055	5	0						
			360D-main	729.17	0	0.78	0.321	3	2	0.65	0.72	0.79	0.69	0.87	1.10
			450D-main	745.82	78.80	0.51	0.075	5	0						
		41867201	540D-main	1167.20	127.25	0.70	0.143	5	0	0.48	1.09	2.48	0.69	0.87	1.10
			720D-main	1354.04	119.47	0.74	0.077	5	0						
			28D-main	607.42	457.98	6.23	0.842	5	0						
		43197901	42D-main	531.94	0	0.66	0.001	4	1						
			51D-main	529.58	0	0.76	0.060	5	0						
			24D-main	564.70	113.51	1.00	0.722	4	0	0.92	1.03	1.15	0.69	0.87	1.10
			86D-main	589.72	144.73	1.04	0.327	4	0						

**Methamidophos Table 3. - Benchmark Dose Calculations for RBC Cholinesterase Measurements Used to Calculate the Oral POD**

MRID no.	Duration of Exposure (# of days)	BMD <sub>10</sub> <sup>a</sup>	BMDL <sup>b</sup>
Oral (mg/kg/day)			
148452	180	0.14	0.14
	360	0.12	0.11
	450	0.11	0.11
	540	0.12	0.12
	720	0.13	0.11
41867201	28	0.088	0.079
	42	0.10	0.082
	51	0.14	0.12
43197901	24	0.048	0.029
	86	0.055	0.043
Oral POD		0.09 mg/kg/day	0.07 mg/kg/day
Dermal (mg/kg/day)			
44525301	22	1.21	0.91
Dermal POD		1.21	0.91
Inhalation (mg/L)			
41402401	28	0.0043	0.0032
	56	0.0058	0.0030
	77	0.0024	0.0019
	91	0.017	0.010
Inhalation POD		0.0046	0.0031

<sup>a</sup> Benchmark dose resulting in 10% reduction in background cholinesterase activity


<sup>b</sup> Lower 95% confidence limit on the BMD<sub>10</sub>

# METHAMIDOPHOS

Methamidophos Figure 1. - Potency Versus Duration of Exposure Graphs


BRAIN

F






PLASMA

M




RBC




# METHAMIDOPHOS

Methamidophos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# METHAMIDOPHOS

Methamidophos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# METHAMIDOPHOS


Methamidophos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# METHAMIDOPHOS


# METHAMIDOPHOS

Methamidophos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# METHAMIDOPHOS

Methamidophos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# METHAMIDOPHOS



Methamidophos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# METHAMIDOPHOS


Methamidophos Figure 8. - Results of Dose-Response Analysis: Dose-Response Curves for Dermal Route of Exposure

44525301 22 D - MAIN



# METHAMIDOPHOS

Methamidophos Figure 9. - Results of Dose-Response Analysis: Dose-Response Curves for Inhalation Route of Exposure



## Methidathion

### Methidathion Table 1. - Toxicology Profile Table

Methidathion						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
43582501	82-7 (870.6200)	90-Day Neurotoxicity–Rat	011659	0/0, 0.20/0.18, 0.66/0.61, 2.01/1.86, 7.19/6.36 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
00160260	83-5 (870.4300)	Chronic Toxicity/Carcinogenicity–Rat	005743 006587	0/0, 0.20/0.26, 2.14/2.68, 5.88/7.92 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

**Methidathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Methidathion																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	00160260	728D-duplicatewhole	2797.81	815.83	0.60	0.109	4	0	0.51	0.60	0.71	0.51	0.60	0.71			
			364D-whole	3479.81	1054.15	1.45	0.526	4	0	0.48	0.80	1.33	0.48	0.80	1.33			
			651D-whole	3019.25	1133.35	0.63	0.863	4	0									
			728D-whole	2764.94	628.17	0.54	0.678	4	0									
	M	00160260	728D-duplicate whole	2699.89	800.20	0.52	0.890	4	0	0.39	0.52	0.68	0.39	0.52	0.68			
			364D-whole	3322.65	0	0.23	0.019	3	1	0.19	0.29	0.44	0.19	0.29	0.44			
			651D-whole	2749.35	0	0.22	0.752	3	1									
			728D-whole	2604.31	858.28	0.53	0.946	4	0									
RBC	F	00160260	728D-duplicate	2103.87	0	0.11	0.136	3	1	0.04	0.08	0.17	0.05	0.29	1.63			
			182D-main	1819.36	0	0.24	0.342	3	1									
			364D-main	2405.59	0	0.01	0.367	3	1									
			546D-main	2393.04	0	0.10	0.052	3	1									
			728D-main	1841.40	0	0.04	0.241	4	0									
	43582501		28D-main	1330.66	108.58	0.84	0.766	5	0	0.72	0.97	1.29						
			56D-main	1850.27	228.78	1.33	0.169	5	0									
			91D-main	1578.32	131.05	0.80	0.485	5	0									
	M	00160260	728D-duplicate	2103.33	1571.38	0.43	0.789	4	0	0.02	0.07	0.23	0.05	0.25	1.14			
			364D-main	2409.94	0	0.03	0.053	4	0									
			546D-main	2120.06	909.32	0.06	0.190	4	0									
			728D-main	1882.83	0	0.03	0.076	4	0									
		43582501	28D-main	1214.78	89.27	0.57	0.827	5	0	0.54	0.65	0.77						
			56D-main	1836.51	295.64	0.72	0.570	5	0									
			91D-main	1677.13	150.03	0.55	0.672	5	0									
Plasma	F	00160260	728D-duplicate	1662.78	772.90	0.21	0.188	4	0	0.17	0.35	0.75	0.28	0.48	0.83			
			182D-main	2464.84	1051.10	0.27	0.195	4	0									
			364D-main	2578.28	1485.38	0.42	0.154	4	0									
			546D-main	2211.93	1150.07	0.38	0.462	4	0									
			728D-main	1925.26	779.14	0.26	0.909	4	0									
	M	00160260	28D-main	1446.63	666.21	0.67	0.820	5	0	0.31	0.67	1.46		0.30	1.13			
			728D-duplicate	986.74	400.17	0.29	0.168	4	0	0.08	0.30	1.13						
			182D-main	544.00	351.65	4.13	0.388	4	0									
			364D-main	801.66	543.26	0.75	0.311	4	0									
			546D-main	913.76	0	0.10	0.955	4	0									
			651D-main	992.83	340.39	0.29	0.575	4	0									
			728D-main	848.00	0	0.03	0.790	4	0									

# METHIDATHION

**Methidathion Figure 1. - Potency Versus Duration of Exposure Graphs**


BRAIN

F





PLASMA

M




RBC




# METHIDATHION

**Methidathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# METHIDATHION




# METHIDATHION

**Methidathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# METHIDATHION




# METHIDATHION

**Methidathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# METHIDATHION

**Methidathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




# METHIDATHION

**Methidathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



# METHIDATHION

Methidathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Methyl Parathion

**Methyl Parathion Table 1. - Toxicology Profile Table**

Methyl Parathion						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00074299	82-1 (870.3199)	Subchronic Feeding–Rat	001882	0, 2.5, 25, 75 ppm 0/0, 0.20/0.16, 2.10/1.64, 6.90/5.90 mg/kg/day (females/males)	Guideline	Rats/ Sprague Dawley
43490501	82-7 (870.6200)	Subchronic Neurotoxicity–Rat	012073	0, 0.5, 5, or 50 ppm 0, 0.03, 0.25, 2.5 mg/kg/day	Guideline	Rats/ Sprague Dawley
41853801	83-1 (870.4100)	Chronic Toxicity with Special Focus on Sciatic Nerve Effects	010333	0, 0.5, 2.5, 12.5, 50 ppm 0, 0.03/0.02, 0.14/0.11, 0.70/0.53, 3.09/2.21 mg/kg/day (females/males)	Nonguideline	Rats/ Sprague Dawley

**Methyl Parathion Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Methyl Parathion																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	41853801	360D-whole	8.630649	0	0.3947	0.0216	4	1	0.311	0.395	0.5	0.31	0.393	0.497			
		00074299	90D-whole	13.76302	2.678872	0.2329	0.874	4	0	0.0221	0.233	2.45						
	M	41853801	360D-whole	7.981011	0	0.0237	0.23	4	1	0.000417	0.0237	1.35	0.0197	0.0553	0.155			
		00074299	90D-whole	12.72864	0	0.0586	0.0693	3	1	0.0202	0.0586	0.17						
RBC	F	41853801	30D-main	7068.996	0	0.1684	0.442	4	1	0.0471	0.0779	0.129	0.0607	0.249	1.02			
			90D-main	7575.456	0	0.0341	0.847	5	0									
			180D-main	6815.121	0	0.0505	0.0906	5	0									
			270D-main	7153.813	0	0.1378	0.716	4	1									
			360D-main	7411.428	0	0.0612	0.0863	5	0									
		43490501	28D-main	1657.661	0	0.4071	0.704	4	0	0.476	1.13	2.68						
			56D-main	1948.489	752.0645	1.7075	0.147	4	0									
			98D-main	1751.79	777.3403	2.2177	0.747	4	0									
	00074299		60D-main	2760.813	981.2055	0.6804	0.81	4	0	0.0271	0.175	1.14						
			90Dmain	2421.826	0	0.0459	0.808	4	0									
	M	41853801	30D-main	8226.059	0	0.0773	0.214	5	0	0.0595	0.0703	0.083	0.0525	0.303	1.75			
			90D-main	8423.415	0	0.0809	0.431	5	0									
			180D-main	6952.402	0	0.0616	0.264	5	0									
			270D-main	5830.079	0	0.0735	0.567	5	0									
			360D-main	7016.751	0	0.0622	0.757	5	0									
		43490501	28D-main	1803.999	624.6239	2.7351	0.786	4	0	1.29	1.76	2.39						
			56D-main	1718.906	806.0729	1.8619	0.739	4	0									
			98D-main	1731.205	0	1.3954	0.185	3	1									
	00074299		60D-main	2708.128	1397.578	1.133	0.971	4	0	0.016	0.185	2.14						
			90Dmain	1912.399	0	0.0331	0.729	4	0									
Plasma	F	41853801	30D-main	1530.479	289.2407	0.7698	0.389	5	0	0.535	0.796	1.18	0.47	0.638	0.867			
			90D-main	2298.363	482.3706	0.9359	0.339	5	0									
			180D-main	2677.879	57.20462	0.537	0.225	5	0									
			270D-main	2469.771	388.1159	0.7826	0.175	5	0									
			360D-main	2536.284	616.1319	0.8717	0.88	5	0									
		43490501	28D-main	1655.948	0	0.6561	0.988	4	0	0.665	0.734	0.81						
			56D-main	2363.554	0	0.7473	0.409	4	0									
			98D-main	2753.307	0	0.7807	0.65	4	0									
		00074299	30D-main	2597.093	964.4877	0.3646	0.103	4	0	0.246	0.381	0.591						
			60D-main	2708.023	929.1068	0.3396	0.97	4	0									
			90Dmain	2977.949	756.8016	0.3992	0.241	4	0									

# METHYL PARATHION

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Plasma (con't)	M	41853801	30D-main	374.9871	149.9925	0.8728	0.223	5	0	0.652	1.08	1.78	0.0591	0.275	1.28
			90D-main	470.8639	159.2061	0.8239	0.111	5	0						
			180D-main	557.0498	209.4905	1.2001	0.478	5	0						
			270D-main	550.4859	226.7451	1.51	0.352	5	0						
			360D-main	661.8549	174.4892	0.8715	0.362	5	0						
		43490501	28D-main	467.4461	0	0.4593	0.693	4	0	0.39	0.437	0.489			
			56D-main	472.429	0	0.4382	0.233	4	0						
			98D-main	476.3506	0	0.4	0.721	4	0						
		00074299	60D-main	1462.881	1025.029	0.2974	0.696	4	0	0.0172	0.0392	0.0891			
			90Dmain	1202.18	0	0.0365	0.149	4	0						


# METHYL PARATHION

Methyl Parathion Figure 1. - Potency Versus Duration of Exposure Graphs




## Methyl Parathion Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

METHYL PARATHION




### Methyl Parathion Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

METHYL PARATHION




## Methyl Parathion Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

METHYL PARATHION




## Methyl Parathion Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

METHYL PARATHION



## Methyl Parathion Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure


METHYL PARATHION



## Methyl Parathion Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure


METHYL PARATHION

41853801 30 D - MAIN




Continuous Exponential Model (Decreasing)

41853801 90 D - MAIN




Continuous Exponential Model (Decreasing)

41853801 180 D - MAIN




Continuous Exponential Model (Decreasing)

41853801 270 D - MAIN




Continuous Exponential Model (Decreasing)

41853801 360 D - MAIN




Continuous Exponential Model (Decreasing)

43490501 28 D - MAIN




Continuous Exponential Model (Decreasing)

43490501 56 D - MAIN




Continuous Exponential Model (Decreasing)

43490501 98 D - MAIN




Continuous Exponential Model (Decreasing)

74299 60 D - MAIN



Continuous Exponential Model (Decreasing)

74299 90 D - MAIN



Continuous Exponential Model (Decreasing)

# MEVINPHOS

## Mevinphos

**Mevinphos Table 1. - Toxicology Profile Table**


Mevinphos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/Nonguideline	Species/Strain
42588501	82-1 (870.3100)	90-Day Subchronic Oral Toxicity Study—Rats	015801	0/0, 0.01/0.05, 0.05/0.50, 0.50/1, 0.75/1 mg/kg/day (females/males)	Guideline	Rat/ CrI:CD BR(SD)
45099101	82-7	Subchronic (13 Week) Neurotoxicity Study of Mevinphos –Rats	014518	0/0, 0.03/0.03, 0.35/0.35, 0.60/0.70 mg/kg/day (females/males)	Guideline	Rat/ SD CrI:CD BR
43088601	83-5 (870.4300)	2-Year Chronic Toxicity/Oncogenicity Study of Mevinphos—Rats	In review	MRID deleted because female controls died prior to termination	In review	Rat/ CrI:CD BR(SD)

**Mevinphos Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Mevinphos																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	42588501	91D-whole	12.30561	0	1.558593	0.007	4	1	1.46	1.56	1.66	1.46	1.56	1.66			
		43088601						MRID deleted because female controls died prior to termination.										
	M	42588501	91D-whole	12.00822	0	1.135227	0.029	3	1	0.95	1.14	1.36	0.95	1.14	1.36			
		43088601						MRID deleted because female controls died prior to termination.										
RBC	F	42588501	49D-main	7800.224	0	0.1473235	0.673	5	0	0.114	0.176	0.273	0.0988	0.602	3.67			
			91D-main	7351.465	0	0.2062003	0.701	5	0									
		45099101	21D- main	1796.313	0	0.9198221	0.0685	4	0	0.897	2.41	6.47						
			49D-main	1897.225	770.388	4.132715	0.603	4	0									
			91D-main	2076.09	1002.69	6.198667	0.412	4	0									
		43088601					MRID deleted because female controls died prior to termination.											
	M	42588501	49D-main	7053.495	0	0.0692517	0.0608	5	0	0.0603	0.0984	0.161	0.0527	0.46	4.01			
			91D-main	8579.318	0	0.102782	0.00219	4	0									
		45099101	21D- main	1968.78	0	1.338713	0.952	3	1	1.1	2.24	4.56						
			49D-main	1892.781	187.969	1.428239	0.599	4	0									
			91D-main	2289.234	812.573	4.155042	0.592	4	0									
		43088601					MRID deleted because female controls died prior to termination.											
Plasma	F	42588501	49D-main	2374.548	164.866	1.904858	0.186	5	0	1.75	2.62	3.92	1.81	2.68	3.96			
			91D-main	2919.698	384.448	2.937777	0.324	5	0									
		45099101	21D-main	1641.571	792.475	21.32133	0.309	4	0	0.752	3.86	19.8						
			49D-main	1771.646	878.785	3.286503	0.628	4	0									
			91D-main	2489.668	0	1.273627	0.915	4	0									
		43088601					MRID deleted because female controls died prior to termination.											
	M	42588501	49D-main	537.4627	267.792	5.711482	0.641	5	0	2.23	3.55	5.64	2.21	3.46	5.4			
			91D-main	522.0296	202.095	2.88174	0.429	4	0									
		45099101	21D-main	429.1258	0	1.150297	0.902	3	1	0.432	2.4	13.3						
			49D-main	400.3671	0	0.6584257	0.554	4	0									
			91D-main	405.9683	258.473	25.18151	0.25	4	0									
		43088601					MRID deleted because female controls died prior to termination.											

# MEVINPHOS


Mevinphos Figure 1. - Potency Versus Duration of Exposure Graphs




## Mevinphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# MEVINPHOS




### Mevinphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# MEVINPHOS




## Mevinphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




## Mevinphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Mevinphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



## Mevinphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



**Naled****Naled Table 1. - Toxicology Profile Table**

Naled						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
45222001	82-2 (870.3200)	28-Day Dermal Toxicity Study--Rats (2000)	0144336	0, 5, 10, 40 mg/kg/day	Guideline	Rat/ Crl:CD (SD)BR
00160750	82-2 (870.3200)	28-Day Dermal Toxicity Study--Rats	5774	0, 1, 20, 80 mg/kg/day	Guideline	Rat/ SD
00164224	82-4 (870.3465)	Thirteen-Week Aerosol Inhalation Toxicology	5784	0, 0.2, 1.2, or 6 µg/L	Guideline	Rat/ Fischer-344
00088871	82-1 (870.3100)	Four-Week Subchronic Oral Toxicity Study	1460	0, 0.25, 1, 10, 100 mg/kg/day	Supplementary	Rat/ SD
00141784	83-5 (870.4300)	Chronic Oral Toxicity/Carcinogenicity Study	002997 004128 004521	0, 0.2, 2, 10 mg/kg/day by gavage	Guideline	Rat/ SD
40087201	82-4 (870.3465)	21-Day Inhalation--Rat	004580 006709	0 (air), 4, 8, 16 µg/L (nominal) actual chamber concentration: 0, 3.4, 7.2, 12.1 µg/L	Supplementary	Rat/ Fischer-344


**Naled Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Naled																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	00088871	28D-whole	10.8106	2.87833	0.1278615	0.466	5	0	0.117	0.128	0.14	0.109	0.17	0.263			
		00141784	714D-whole	7.27375	2.54863	0.2441632	0.549	4	0	0.174	0.244	0.342						
	M	00088871	28D-whole	10.5088	2.68647	0.1282613	0.126	5	0	0.115	0.128	0.144	0.111	0.15	0.21			
		00141784	742D-whole	7.17192	2.32693	0.2134431	0.945	4	0	0.144	0.213	0.316						
RBC	F	00141784	175D	2027.89	0	0.00474115	0.186	4	0	0.0607	0.0958	0.151	0.0263	0.05	0.113			
			357D	2666.4	0	0.08093208	0.72	3	1									
			539D	2241.87	0	0.07067627	0.0767	3	1									
			714D	2172.36	0	0.1536224	0.975	3	1									
		00088871	28D	1738.09	0	0.03329722	0.385	4	1	0.0256	0.0333	0.0432	0.0235	0.03	0.0449			
		00141784	182D	3064.27	0	0.2083537	0.71	3	1	0.0196	0.0726	0.268						
			364D	2684.91	0	0.021312	0.23	4	0									
			546D	2257.21	1278.24	0.1140422	0.424	4	0									
			728D	2133.77	976.571	0.07826447	0.0877	4	0									
			00088871	28D	1801.96	0	0.03077814	0.991	4	1	0.022	0.0308	0.043					
Plasma	F	00141784	175D	3338.29	1250.94	0.3037001	0.134	4	0	0.174	0.241	0.335	0.0867	0.16	0.282			
			357D	3027.68	0	0.1632189	0.0493	3	1									
			539D	2781.57	1038.93	0.3649978	0.564	4	0									
			714D	2378.72	0	0.2167434	0.012	3	1									
			00088871	28D	1878.53	495.459	0.1031324	0.499	5	0	0.0782	0.103	0.136					
		00141784	182D	677.843	292.599	0.4069834	0.494	4	0	0.373	0.503	0.679	0.0261	0.15	0.81			
			364D	1007.63	407.822	0.6268904	0.475	4	0									
			546D	1132.68	420.846	0.462995	0.114	4	0									
			728D	1168.31	465.599	0.4108957	0.368	4	0									
			00088871	28D	475.051	0	0.04223011	0.598	4	1	0.0324	0.0422	0.0551					


## Naled Figure 1. - Potency Versus Duration of Exposure Graphs

NALED


BRAIN






PLASMA




RBC



M




## Naled Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




NALED

### Naled Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




NALED

## Naled Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




NALED

## Naled Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




NALED

## Naled Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



NALED

## Naled Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



NALED

**Oxydemetonmethyl****Oxydemetonmethyl Table 1. - Toxicology Profile Table**

Oxydemeton Methyl						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00151806	83-5 870.4300	Chronic Toxicity/oncogenicity Study–Rat	005174 005752 009544	0/0, 0.06/0.05, 0.62/0.49, 6.92/5.84 mg/kg/day (females/males)	Guideline	Rat/ Fischer
00143351	82-1 870.3100	Subchronic Toxicity–Rat	005752	0/0, 0.09/0.08, 0.93/0.75, 13.22/8.25 mg/kg/day (females/males)	Supplementary	Rat/ SPF
41834002		Special NTP Study	012221	0, 0.15, 0.45 or 2.5 mg/kg/day a.i. (males only)	Nonguideline	Rat/ Sprague Dawley
44189501	82-7 870.6200	Subchronic Neurotoxicity–Rat	012212	0, 0.005, 0.02, 0.05, 0.50, 4 mg/kg/day	Guideline	Rat/ Sprague Dawley
44141301		13-week Cholinesterase Study–Rat	012216	0, 0.005, 0.02, 0.05, 0.50, 4 mg/kg/day	Nonguideline	Rat/ Sprague Dawley

**Oxydemetonmethyl Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Oxydemeton Methyl																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	00143351	90D-whole	1.970201	0	1.331147	0.0000974	3	1	1.18	1.33	1.5	1.4	1.69	2.04			
		151806	810D-whole	12.48674	1.99968	1.440656	0.604	4	0	1.3	1.44	1.6						
		44141301	28D-whole	10.3393	2.286858	2.028372	0.313	6	0	1.94	2.03	2.13						
			56D-whole	9.360266	2.077204	2.018243	0.662	6	0									
			91D-whole	9.81174	2.097718	2.064113	0.759	6	0	1.95	2.03	2.12						
		44189501	28D-whole	10.3469	2.28681	2.029197	0.178	6	0									
			56D-whole	9.360266	2.077204	2.018243	0.596	6	0									
			91D-whole	9.81174	2.097718	2.064113	0.706	6	0									
	M	143351	90D-whole	1.219717	0	0.555742	0.15	3	1	0.429	0.556	0.721	1.02	1.58	2.45			
		151806	30D-whole	12.65844	1.4998	1.657448	0.00133	4	0	1.61	1.8	2.02						
			810D-whole	12.08189	1.699905	1.947044	0.931	4	0									
		41834002	93D-whole	12.45683	2.623193	1.930375	0.106	4	0	1.8	1.93	2.07						
		44141301	28D-whole	10.19361	2.300063	2.262649	0.625	6	0	2.08	2.18	2.28						
			56D-whole	9.26511	2.098874	2.133611	0.247	6	0									
			91D-whole	9.640871	2.118562	2.096977	0.935	6	0									
		44189501	28D-whole	10.19361	2.300063	2.262649	0.555	6	0	2.09	2.18	2.27						
			56D-whole	9.26511	2.098874	2.133611	0.177	6	0									
			91D-whole	9.640871	2.118562	2.096977	0.918	6	0									
RBC	F	00143351	28D-main	3077.527	0	0.288233	0.521	3	1	0.228	0.261	0.298	0.251	0.448	0.8			
			90D-main	2617.718	0	0.255605	0.00305	3	1									
		151806	210D-main	1624.055	0	0.28886	0.538	3	0	0.209	0.667	2.12						
			360D-main	1460	289.9991	2.041394	Insufficient degrees of freedom to compute a GOF test	3	0									
			540D-main	1120.807	0	0.150607	0.000001	3	0									
			810D-main	1435.675	209.8838	2.205995	0.194	4	0									
			28d-main	2038.755	0	0.433055	0.693	5	1	0.54	0.678	0.85						
		44189501	56D-main	2344.509	0	0.745159	0.878	5	1									
			91D-main	1986.365	0	0.783842	0.494	5	1									

# OXYDENEONMETHY

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
RBC (con't)	M	143351	28D-main	2967.352	0	0.426778	0.167	3	1	0.352	0.398	0.449	0.51	0.994	1.94			
			90D-main	2634.842	0	0.375239	0.00318	3	1									
		151806	30D-main	1647.894	0	0.6377	0.0000162	3	1	1.24	1.69	2.29						
			180D-main	1602.721	0	2.05553	0.00052	3	1									
		41834002	210D-main	1320	249.9648	1.767594	Insufficient degrees of freedom to compute a GOF test	3	0	1.22	2.05	3.45						
			360D-main	1726.995	0	1.889664	0.0185	3	1									
			540D-main	1877.553	259.7432	2.238172	0.00164	4	0									
			720D-main	1441.943	309.7269	1.847156	0.105	4	0									
			810D-main	1462.514	249.9116	2.201196	0.489	4	0									
			25D-main	2474.998	0	1.113769	0.232	3	1									
		44189501	58D-main	2462.293	1160.613	3.253094	0.0243	4	0	0.409	0.763	1.43						
			92D-main	2550.34	1280.681	2.442008	0.185	4	0									
			28D-main	2026.494	0	0.433364	0.796	5	1									
Plasma	F	143351	56D-main	2131.277	0	0.633448	0.139	5	1	0.162	0.731	3.29	0.918	1.43	2.23			
			91D-main	2151.517	918.1059	1.648448	0.749	6	0									
		151806	28D-main	977.1388	35.51319	0.230895	0.0813	4	0	0.621	1.02	1.68						
			90D-main	1539.182	0	2.037537	0.00000295	3	1									
			30D-main	1778.045	249.2337	1.100512	0.823	4	0									
			180D-main	2319.626	91.70877	0.69396	0.178	4	0									
			210D-main	2754.269	209.5123	1.243939	0.439	4	0									
			360D-main	2385.428	176.1528	0.917537	0.633	4	0									
		44189501	540D-main	2461.505	199.5909	3.259881	0.213	4	0	1.46	1.99	2.71						
			720D-main	1969.253	0	0.335527	0.4	4	0									
			810D-main	2230	209.724	1.285873	Insufficient degrees of freedom to compute a GOF test	3	0									
			28D-main	1558.635	392.628	1.348994	0.107	6	0									
			56D-main	2141.665	513.4299	2.591007	0.15	6	0									
			91D-main	2184.728	549.4514	1.796132	0.684	6	0									


# OXYDEMETHONEMETHY

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Plasma (con't)	M	143351	28D-main	481.2344	0	0.251662	0.0553	4	0	0.243	0.252	0.261	0.421	0.892	1.89			
			90D-main	479.4599	275.9502	0.473733	0.43	4	0									
		151806	30D-main	423.9429	0	0.143717	0.0000587	3	1	0.815	1.13	1.57						
			180D-main	649.8545	158.2672	0.970541	0.0807	4	0									
			210D-main	783.8245	129.705	1.357291	0.047	4	0									
			360D-main	709.1758	66.65997	0.900578	0.98	4	0									
			540D-main	829.6335	122.1155	0.769864	0.302	4	0									
			720D-main	1335.162	119.8381	1.516956	0.493	4	0									
			810D-main	1732.857	160.0101	2.076774	0.71	4	0									
		41834002	25D-main	391.9147	115.757	1.659662	0.504	4	0	1.07	1.5	2.11						
			58D-main	376.6983	91.63535	1.4216	0.0867	4	0									
			92D-main	377.4309	98.4559	1.022847	0.434	4	0									
		44189501	28D-main	322.8097	151.6727	1.843453	0.174	6	0	1.14	1.57	2.15						
			56D-main	293.3594	140.1592	1.207211	0.575	6	0									
			91D-main	295.6208	151.2712	1.537914	0.402	6	0									


# OXYDEMETHONMETHYL

Oxydemetonmethyl Figure 1. - Potency Versus Duration of Exposure Graphs





BRAIN



PLASMA





RBC




# OXYDEMETHONMETHYL

Oxydemetonmethyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




**Oxydemetonmethyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




**Oxydemetonmethyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**


# OXYDEMETHONMETHYL


Oxydemetonmethyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# OXYDEMETHONEMETHYL



**Oxydemetonmethyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

**Oxydemetonmethyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

**Phorate****Phorate Table 1. - Toxicology Profile Table**


Phorate						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
00125233	83-5 (870.4300)	2-Year Feeding/Oncogenicity–Rats	013731	0, 0.05, 0.15, 0.30 mg/kg/day	Guideline	CRL:COBS CD (SD)BR
44895302	82-7 (870.6200)	13-Week Dietary Neurotoxicity Study	13767	0/0, 0.04/0.04, 0.08/0.07, 0.33/0.54 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
44895301	82-1 (870.3100)	Rangefinding Dietary Neurotoxicity	137767	0/0, 0.10/0.09, 0.20/0.19, 0.52/0.69 mg/kg/day (females/males)	Supplementary	Not Stated

**Phorate Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Phorate																			
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency				
Brain	F	00125233	720D-whole	2744.38	0	2.24	0.187	3	0	1.22	2.24	4.13	0.26	0.71	1.99				
		44895301	21D-whole	19355.92	0	0.34	0.892	3	1	0.20	0.34	0.57							
		44895302	91D-whole	17896.51	0	0.42	0.378	3	1	0.12	0.42	1.51							
			91D-whole duplicate	20538.86	0	3.37	0.040	4	0	2.71	3.37	4.19							
		44895301	21D-whole	19003.59	0	0.01	0.676	3	1	6.18E-15	0.01	1.65E+10		1.36	1.56	1.79			
		44895302	91D-whole	18478.54	0	1.56	0.268	4	0	1.36	1.56	1.79							
			91D-whole duplicate	18619.35	0	1.19	0.346	4	0	0.96	1.19	1.47							
RBC	F	44895301	21D-main	1222.64	0	2.42	0.020	3	1	1.33	2.42	4.39	3.88	4.49	5.2				
		44895302	91D-duplicate	1920.56	0	5.17	0.055	4	0	4.02	4.67	5.43							
			28D-main	1394.97	0	5.02	0.823	4	0										
			56D-main	1226.00	0	1.45	0.195	3	1										
			91D-main	1950.41	0	4.40	0.019	4	0										
		44895301	21D-main	1362.20	0	3.13	0.534	4	0	2.53	3.13	3.87							
	M	44895302	91D-duplicate	1802.47	0	2.51	0.736	4	0	2.59	2.97	3.42		2.69	3.02	3.39			
			28D-main	1289.66	0	3.51	0.956	4	0										
			56D-main	1169.86	0	0.23	0.593	3	1										
			91D-main	1636.96	0	2.96	0.347	4	0										
		00125233	90D-main	1565.89	0	3.06	0.429	4	0	2.83	3.49	4.31	3.07	3.39	3.75				
			120D-main	2171.14	0	4.01	0.500	4	0										
			720D-main	1968.62	0	3.36	0.842	4	0										
		44895301	21D-main	1716.05	0	3.02	0.185	4	0	2.36	3.02	3.85							
		44895302	91D-duplicate	2915.27	0	4.45	0.105	4	0	3.05	3.46	3.93							
			28D-main	1361.02	0	2.94	0.016	4	0										
			56D-main	2143.70	0	3.53	0.008	4	0										
			91D-main	2484.12	0	3.27	0.015	4	0										
		00125233	360D-main	739.00	0	1.88	0.536	4	0	0.55	0.86	1.34	0.45	0.958	2.02				
			720D-main	1550.95	590.78383	11.55	0.369	4	0										
		44895301	21D-main	544.19	0	0.50	0.038	4	0										
		44895302	91D-duplicate	584.27	255.00	2.70	0.594	4	0										
			28D-main	512.51	0	0.84	0.339	4	0										
			56D-main	577.83	143.83939	1.92	0.571	4	0										
			91D-main	570.24	143.66215	1.54	0.196	4	0										

## Phorate Figure 1. - Potency Versus Duration of Exposure Graphs


BRAIN






PLASMA



RBC




PHORATE




# PHORATE

Phorate Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# PHORATE

Phorate Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




## Phorate Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

PHORATE




## Phorate Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure


PHORATE



## Phorate Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



PHORATE

**Phorate Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

## Phosalone

**Phosalone Table 1. - Toxicology Profile Table**

Phosalone						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/Nonguideline	Species/Strain
44801002	83-5 (870.4300)	Combined Chronic/Oncogenicity–Rats	13753	0/0, 0.28/0.24, 2.87/2.19, 46.50/31.80 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
44852504	82-7 (870.6200)	13-Week Neurotoxicity Feeding –Rats	13753	0/0, 5/4.6, 14.70/13.80, 61.90/55.80 mg/kg/day (females/males)	Guideline	Rat/ Crl:CDBR


**Phosalone Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**

Phosalone															
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency
Brain	F	44801002	728D-whole	5.92	0	0.03	3.51E-05	4	0	0.02	0.03	0.03	0.02	0.02	0.03
		44852504	91D-whole	7.36	0	0.01	0.110	3	1	0.01	0.01	0.03			
			28D-whole duplicate	7.65	0	0.03	0.078	4	0	0.02	0.03	0.03	0.02	0.03	0.03
			56D-whole duplicate	5.54	0	0.02	0.373	4	0						
	M	44801002	728D-whole	5.16	0	0.04	0.992	4	0	0.04	0.04	0.05	0.02	0.03	0.05
		44852504	91D-whole	8.44	0	0.02	0.386	4	0	0.02	0.02	0.02			
			28D-whole duplicate	7.34	0	0.01	0.865	4	0	0.02	0.03	0.06	0.02	0.03	0.06
			56D-whole duplicate	6.88	1.61	0.04	0.102	4	0						
RBC	F	44801002	91D-main	1233.90	0	0.15	0.603	3	0	0.05	0.13	0.31	0.02	0.05	0.14
			182D-main	1434.85	0	0.17	0.228	3	0						
			364D-main	1300.63	0	0.24	0.682	3	0						
			546D-main	1528.99	0	0.02	0.854	3	0						
			728D-main	2391.56	519.95	0.29	0.896	4	0						
		44852504	28D-duplicate	3351.24	0	0.03	0.186	3	1	0.02	0.03	0.04			
			56D-duplicate	2874.57	0	0.04	0.347	3	1						
			91D-main	2534.44	0	0.03	0.111	3	1						
	M	44801002	91D-main	1211.89	0	0.12	0.873	3	0	0.04	0.11	0.26	0.04	0.09	0.20
			182D-main	1372.71	0	0.20	0.244	3	0						
			546D-main	1705.37	0	0.23	0.824	3	0						
			728D-main	1685.68	0	0.03	0.885	4	0						
		44852504	28D-duplicate	2481.63	1976.14	0.05	0.705	4	0	0.00	0.03	0.22			
			56D-duplicate	2229.24	0	4.70E-03	0.140	4	0						
			91D-main	2723.58	1073.23	0.14	0.473	4	0						
Plasma	F	44801002	91D-main	1487.17	369.80	0.20	0.309	4	0	0.13	0.18	0.23	0.07	0.12	0.20
			182D-main	1461.66	319.20	0.16	0.356	4	0						
			364D-main	1314.39	409.56	0.17	0.714	4	0						
			546D-main	1416.57	479.61	0.17	0.965	4	0						
			728D-main	1225.91	439.61	0.17	0.439	4	0						
		44852504	28D-duplicate	885.53	98.31	0.07	0.127	4	0	0.07	0.08	0.09			
			56D-duplicate	1161.50	118.80	0.07	0.077	4	0						
			91D-main	1128.80	124.45	0.09	0.783	4	0						
	M	44801002	91D-main	414.34	0	0.02	0.069	4	0	0.02	0.04	0.09	0.03	0.04	0.06
			182D-main	404.61	149.13	0.06	0.055	4	0						
			364D-main	484.66	0	0.02	0.338	4	0						
			546D-main	660.74	266.90	0.07	0.277	4	0						
			728D-main	795.43	258.14	0.18	0.771	4	0						
		44852504	28D-duplicate	367.63	44.87	0.04	0.228	4	0	0.03	0.04	0.06			
			56D-duplicate	379.22	59.31	0.04	0.060	4	0						
			91D-main	380.73	71.13	0.06	0.371	4	0						


# PHOSALONE

Phosalone Figure 1. - Potency Versus Duration of Exposure Graphs





BRAIN



PLASMA




RBC




# PHOSALONE

Phosalone Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Responce Curves for Oral Route of Exposure




# PHOSALONE

Phosalone Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# PHOSALONE

Phosalone Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# PHOSALONE

Phosalone Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# PHOSALONE

Phosalone Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# PHOSALONE

Phosalone Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure









**Phosmet****Phosmet Table 1. - Toxicology Profile Table**


Phosmet						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41916401	83-5 (870.4300)	Chronic/Oncogenicity–Rat	9828 10756	0/0, 1.1/1.1, 2.1/1.8, 10.9/9.4, 27.1/22.7 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
44811801	82-7 (870.6200)	Subchronic Neurotoxicity –Rat	13522	0/0, 1.9/1.7, 3.9/3.4, 12.1/10.4 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley

**Phosmet Table 2. - Results of Dose-Response Analysis: Exponential Parameter Estimates for Oral Route of Exposure**


Phosmet																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	41916401	360D-whole	1.43	0.68	0.08	0.169	5	0	0.02	0.04	0.09	0.08	0.09	0.10			
			720D-whole	1.83	0	0.02	0.080	4	0									
		44811801	21D-whole	25.48	0	0.08	0.062	4	0	0.08	0.09	0.10						
			49D-whole	22.96	0	0.10	0.111	4	0									
		41916401	360D-whole	1.60	0.84	0.07	0.489	5	0	1.51E-02	0.02	0.03	0.02	0.03	0.07			
			720D-whole	1.94	0	0.02	0.002	4	0									
		44811801	21D-whole	23.26	0	0.03	0.217	3	1	0.04	0.05	0.07						
			49D-whole	21.17	0	0.06	0.468	4	0									
RBC	M	41916401	180D-main	1570.72	111.08	0.17	0.878	5	0	0.11	0.15	0.20	0.12	0.14	0.18			
			360D-main	1431.12	247.06	0.25	0.051	5	0									
			540D-main	1538.87	0	0.13	0.513	4	0									
			720D-main	1705.62	0	0.11	0.650	4	0									
		44811801	21D-main	2456.37	0	0.09	0.067	4	0	0.09	0.14	0.20						
			49D-main	2293.16	0	0.18	0.211	4	0									
			91D-main	1600.95	0	0.20	0.046	3	0									
		41916401	180D-main	1802.68	435.50	0.27	0.277	5	0	0.12	0.16	0.22	0.10	0.12	0.15			
			360D-main	1414.81	293.81	0.20	0.250	5	0									
			540D-main	1476.20	0	0.13	0.764	4	0									
			720D-main	1842.83	0	0.11	0.954	4	0									
		44811801	21D-main	3714.13	0	0.10	0.807	4	0	0.10	0.11	0.12						
			49D-main	3411.72	0	0.11	0.110	4	0									
			91D-main	3622.08	0	0.11	0.648	4	0									
Plasma	F	41916401	180D-main	3561.92	608.31	0.08	0.318	5	0	0.06	0.10	0.15	0.07	0.11	0.15			
			360D-main	2120.27	571.14	0.09	0.990	5	0									
			540D-main	2968.71	1631.87	0.30	0.352	4	0									
			720D-main	2191.85	973.85	0.15	0.318	4	0									
		44811801	21D-main	2676.34	630.86	0.23	0.603	4	0	0.07	0.13	0.25						
			49D-main	2858.53	0	0.08	0.246	4	0									
			91D-main	3129.27	1649.79	0.25	0.215	4	0									
		41916401	180D-main	670.11	325.65	0.07	0.870	5	0	0.02	0.10	0.39	0.03	0.04	0.06			
			360D-main	707.49	222.21	0.06	0.821	5	0									
			540D-main	1354.78	622.34	0.61	0.945	4	0									
			720D-main	917.14	0	0.02	0.768	4	0									
		44811801	21D-main	559.74	259.99	0.14	0.648	4	0	0.03	0.04	0.06						
			49D-main	539.02	0	0.02	0.238	4	0									
			91D-main	581.86	0	0.04	0.706	4	0									

**Phosmet Figure 1. - Potency Versus Duration of Exposure Graphs****BRAIN****PLASMA****RBC**


## Phosmet Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




### Phosmet Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




**Phosmet Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




**Phosmet Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



**Phosmet Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



**Phosmet Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**



# Pirimiphos Methyl

## Pirimiphos Methyl Table 1. -Toxicology Profile Table

Pirimiphos Methyl						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/Nonguideline	Species/Strain
00129343	82-1 (870.3100)	Subchronic Feeding–Rat	014067 3582	0, 0.25, 0.40, 0.50, 2.50 mg/kg/day	Guideline	Rat/ Wistar
43608201	82-7 (870.6200)	90-Day Subchronic Neurotoxicity–Rat	12054	0/0, 0.2/0.2, 2.4/2.1, 24.7/21.1 mg/kg/day (females/males)	Guideline	Rat/ Sprague Dawley
92147035	83-5 (870.4300)	Chronic Toxicity/Carcinogenicity–Rat	14067 3582 5105 8819	0, 0.5, 2.5, 15 mg/kg/day	Guideline	Rat/ Wistar

**Pirimiphos Methyl Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure**

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency					
Brain	F	92147035	00129343	28D-whole	34.9768619	0	0.062875	0.49	5	0	0.0396	0.0629	0.0997	0.0213	0.0383	0.069				
				84D-whole	31.5269706	0	0.025156	0.0984	4	0	0.0237	0.0264	0.0294							
				182D-whole	27.096617	0	0.031785	0.555	4	0										
				364D-whole	25.3348149	0	0.026703	0.141	4	0										
				728D-whole	26.2441737	0	0.014819	0.674	4	0										
	M	92147035	00129343	28D-whole	31.025261	0	0.034889	0.729	5	0	0.0133	0.0349	0.0915	0.0134	0.0276	0.057				
				84D-whole	31.9112615	0	0.01211	0.518	4	0	0.00686	0.0205	0.0613							
				182D-whole	34.4903698	0	0.105504	0.564	3	1										
				364D-whole	27.3438736	0	0.004982	0.232	4	0										
				728D-whole	27.2603035	0	0.026349	0.15	4	0										
RBC	F	00129343	28D-duplicate	896.931183	0	0.01069	0.747	5	0	0.0153	0.0538	0.189	0.0244	0.034	0.0475					
			21D-main	1028.622	0	0.056989	0.592	5	0											
		43608201	21D-main	2042.85	0	0.023471	0.66	4	0	0.0157	0.0384	0.0941								
			49D-main	2038.01773	1061.4575	0.124952	0.704	4	0											
			91D-main	2041.314	1095.141	0.069763	0.874	4	0											
			28D-main	1220.622	234.546	0.069907	0.604	4	0											
			42D-main	1387.321	46.59597	0.034112	0.178	4	0											
			56D-main	1272.56064	661.29342	0.129177	0.153	4	0											
			84D-main	1337.159	0	0.027445	0.834	4	0											
			182D-main	1601.378	633.1516	0.072312	0.375	4	0											
			273D-main	1342.44926	663.44631	0.102312	0.638	4	0											
	M	92147035	364D-main	1107.9418	482.70638	0.123893	0.573	4	0	0.022	0.032	0.0465								
			455D-main	1229.026	0	0.025725	0.815	4	0											
			546D-main	1107.55006	527.14145	0.10381	0.108	4	0											
			637D-main	1062.071	0	0.03076	0.602	4	0											
			728D-main	1535.151	848.3205	0.081913	0.0914	4	0											
			28D-duplicate																	
			21D-main																	
			21D-main	2011.5314	1066.0512	0.200097	0.762	4	0	0.0152	0.0401	0.105	0.025	0.0319	0.0407					
			49D-main	2008.99	0	0.024133	0.405	4	0											
			91D-main	2085.014	0	0.022725	0.896	4	0											
			28D-main	1131.64897	924.29321	0.257713	0.673	4	0	0.0244	0.0314	0.0404								
			42D-main	1183.153	0	0.024732	0.706	4	0											
			56D-main	940.713222	0	0.024174	0.755	4	0											
			84D-main	1445.568	657.6992	0.071058	0.0575	4	0											
			182D-main	1495.04442	777.09938	0.117962	0.366	4	0											
			273D-main	1128.163	0	0.03945	0.735	4	0											
			364D-main	1098.816	0	0.014723	0.553	4	0											
			455D-main	1468.241	0	0.011075	0.673	4	0											
			546D-main	992.046165	200.55244	0.056435	0.804	4	0											
			637D-main	1041.76842	0	0.040525	0.571	4	0											
			728D-main	999.966007	608.05587	0.104333	1	4	0											


# PRIMPHOS METHYL

Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Plasma	F	00129343	28D-duplicate	1962.77481	0	0.378925	0.269	5	0	0.289	0.34	0.4	0.36	0.439	0.536			
			21D-main	1963.28246	0	0.302913	0.319	5	0									
		43608201	21D-main	1638.23653	274.87407	0.475259	0.0535	4	0	0.441	0.524	0.622						
			49D-main	2052.6792	295.75459	0.497038	0.0541	4	0									
			91D-main	2654.66808	245.63896	0.555562	0.0555	4	0									
		92147035	28D-main	3924.85759	643.42262	0.418858	0.656	4	0	0.432	0.472	0.516						
			42D-main	4202.32742	1101.3352	0.550972	0.548	4	0									
			56D-main	3725.81844	745.01256	0.422022	0.783	4	0									
			84D-main	3601.90221	597.63018	0.509059	0.61	4	0									
			182D-main	4106.89905	665.48846	0.445453	0.856	4	0									
			273D-main	3535.28922	387.34404	0.470515	0.912	4	0									
			364D-main	3804.72484	378.14599	0.377809	0.986	4	0									
			455D-main	2959.83261	339.37786	0.485863	0.16	4	0									
			546D-main	2690.36351	289.36729	0.531734	0.77	4	0									
			637D-main	2539.4945	356.60001	0.419756	0.419	4	0									
	M	00129343	728D-main	3117.09783	597.79541	0.480295	0.86	4	0	0.121	0.146	0.177	0.132	0.157	0.186			
			28D-duplicate	715.954199	0	0.147966	0.25	5	0									
			21D-main	607.84981	0	0.142896	0.589	5	0									
		43608201	21D-main	426.024023	210.24304	0.393065	0.0411	4	0	0.157	0.26	0.431						
			49D-main	405.996205	198.68056	0.289956	0.213	4	0									
			91D-main	361.612744	0	0.144549	0.117	3	1									
			28D-main	693.401682	182.22849	0.070406	0.899	4	0									
		92147035	42D-main	802.499105	109.87584	0.060337	0.407	4	0	0.0881	0.15	0.257						
			56D-main	796.112528	316.39498	0.13467	0.887	4	0									
			84D-main	656.530649	0	0.037814	0.663	4	0									
			182D-main	563.246131	227.21322	0.137249	0.363	4	0									
			273D-main	626.052712	228.4314	0.168381	0.129	4	0									
			364D-main	778.133221	209.74078	0.093347	0.188	4	0									
			455D-main	779.357077	131.72923	0.208889	0.584	4	0									
			546D-main	793.399166	256.91138	0.339713	0.633	4	0									
			637D-main	659.744668	267.15147	0.328296	0.992	4	0									
			728D-main	615.708548	183.74125	0.218971	0.719	4	0									


# Pirimiphos Methyl Figure 1. - Potency Versus Duration of Exposure Graphs

PIRIMIPHOS METHYL


BRAIN






PLASMA



RBC




M




## Pirimiphos Methyl Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

PIRIMIPHOS METHYL




### Pirimiphos Methyl Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

PIRIMIPHOS METHYL




## Pirimiphos Methyl Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

PIRIMIPHOS METHYL




# PIRIMIPHOS METHYL




## Pirimiphos Methyl Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

PIRIMIPHOS METHYL




# PIRIMIPHOS METHYL




## Pirimiphos Methyl Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure


PIRIMIPHOS METHYL




# PIRIMIPHOS METHYL



## Pirimiphos Methyl Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# PIRIMIPHOS METHYL



## Terbufos







**Terbufos Table 1. - Toxicology Profile Table**

Terbufos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/Nonguideline	Species/Strain
00109446	82-1 (870.3100)	Subchronic Toxicity Study–Rat	002377 005612	0/0, 0.01/0.01, 0.02/0.02, 0.05/0.04, 0.095/0.08 mg/kg/day (females/males)	Guideline	Rat/ SD
40089602	83-1 (870.4100)	One-year Dietary Toxicity Study–Rat	006352	0/0, 0.009/0.007, 0.04/0.03, 0.07/0.06 mg/kg/day (females/males)	Guideline	Rat/ CD (SD derived) (COBs)
00049236	83-5 (870.4300)	Combined Chronic Toxicity/Carcinogenicity Study–Rats	004898 003847 (ChE) 001514 005612	0/0, 0.01/0.01, 0.05/0.04, 0.22/0.33 mg/kg/day (females/males)	Guideline	Rat/ Long Evans
44842302	82-7 (870.6200)	Subchronic Neurotoxicity Study–Rat (1999)	013572	0/0, 0.04/0.04, 0.06/0.06, 0.25/0.37 mg/kg/day (females/males)	Guideline	Rat/ Crl:CD(SD)IGS


**Terbufos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure**

Terbufos																								
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency									
Brain	F	00109446	90D-whole	2.42	0	0.45	0.970	5	0	0.05	0.45	3.77	4.17	4.88 (brain-F-	5.73									
		40089602	364D-whole	9.39	0	1.46	0.171	4	0	0.82	1.46	2.58	1.54	2.89 (brain-F-whole)	5.41									
		44842302	91D-duplicate whole	20.12	0	4.88	0.003	4	0	4.17	4.88	5.73												
			91D-whole	20.74	0	5.38	1.03E-07	4	0	4.87	5.38	5.94												
		00049236	90D-whole	1.43	0	1.97	0.870	3	1	3.46	3.91	4.41												
			720D-whole	1.56	0	3.96	0.215	4	0															
	M	00109446	90D-whole	2.47	0	0.93	0.298	5	0	0.35	0.93	2.47	2.01	2.3 (brain-M-	2.63									
		40089602	364D-whole	9.39	0	1.29	0.069	4	0	0.81	1.29	2.05	1.39	2.05 (brain-M-whole)	3.02									
		44842302	91D-duplicate whole	18.72	0	2.30	0.060	4	0	2.01	2.30	2.63												
			91D-whole	19.18	0	2.45	0.051	4	0	2.22	2.45	2.69												
		00049236	90D-whole	1.48	0	2.93	0.156	4	0	2.81	3.04	3.28												
			720D-whole	1.53	0	3.10	0.148	4	0															
RBC	F	00109446	30D-main	14.96	0	0.26	0.067	5	0	0.02	0.24	2.51	0.45	2.01	8.94									
			60D-main	14.50	0	0.18	0.489	5	0															
			90D-main	13.80	0	0.23	0.850	5	0															
		40089602	42D-main	5717.12	0	0.10	0.285	4	0	0.12	0.47	1.86												
			91D-main	4762.94	0	1.00	0.776	4	0															
	44842302		182D-main	7066.18	0	0.45	0.368	4	0															
			364D-main	7747.49	0	0.44	0.567	4	0															
			91D-duplicate	1200.84	0	4.03	0.182	3	1	3.03	10.60	37.00												
			28D-main	Did not converge to exponential function																				
			56D-main	1395.32	0	3.53	0.312	3	1															
			91D-main	1325.37	0	6.44	0.413	3	1															
	00049236		30D-main	0.29	0	2.63	0.051	4	0	2.73	5.75	12.10												
			90D-main	0.45	0.08	15.57	0.902	4	0															
			180D-main	0.51	0	3.83	0.988	4	0															
			360D-main	0.69	0	2.48	0.360	4	0															
			540D-main	0.51	0.07	5.26	0.867	4	0															
			720D-main	0.43	0.15	20.51	0.994	4	0															
	M	00109446	30D-main	14.11	0	2.10	0.291	3	2	0.23	1.24	6.78	1.17	3.79	12.30									
			60D-main	15.44	0	0.42	0.131	5	0															
			90D-main	11.18	0	0.37	0.545	4	1															
		40089602	42D-main	5380.27	0	1.54	0.740	4	0	0.54	0.96	1.72												
			91D-main	6225.73	0	1.29	0.503	4	0															
			182D-main	7109.12	0	0.85	0.832	4	0															
			364D-main	8929.19	0	0.40	0.090	4	0	10.20	12.90	16.40												
		44842302	91D-duplicate	1202.45	0	5.97	0.042	3	1															
			28D-main	1388.05	0	16.15	0.163	4	0															
			56D-main	1382.67	12.33	10.75	0.706	4	0															
			91D-main	1515.13	0	11.85	0.571	4	0															


Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
RBC (con't)	M (con't)	00049236	30D-main	0.33	0	1.36	0.341	4	0	3.68	9.25	23.30	1.17 (con't)	3.79 (con't)	12.30 (con't)			
			90D-main	0.44	0.14	13.85	0.882	4	0									
			180D-main	0.52	0.16	19.71	0.696	4	0									
			360D-main	0.51	0.27	6.77	0.800	4	0									
			540D-main	0.58	0.22	16.90	0.612	4	0									
			720D-main	0.40	0.15	17.94	0.946	4	0									
Plasma	F	00109446	30D-main	1553.30	0	6.56	0.093	5	0	5.62	7.03	8.81	5.50	6.43	7.53			
			60D-main	2029.27	0	6.74	0.465	5	0									
			90D-main	2678.78	0	7.65	0.513	5	0									
		40089602	42D-main	1604.96	0	7.48	0.156	4	0	5.34	6.94	9.03						
			91D-main	2215.45	0	7.11	0.038	4	0									
			182D-main	2676.11	0	1.84	0.386	3	1									
			364D-main	2521.26	0	6.12	0.080	4	0									
		44842302	91D-duplicate	3204.49	0	10.20	0.152	4	0	2.25	4.57	9.26						
			28D-main	1323.25	0	2.16	0.953	3	1									
			56D-main	1844.81	0	2.78	0.267	3	1									
			91D-main	2163.71	0	3.25	0.073	3	1									
		00049236	90D-main	1.02	0.25	11.55	0.948	4	0	2.44	3.93	6.32						
			180D-main	1.43	0	4.02	0.237	4	0									
			360D-main	1.46	0	0.64	0.034	3	0									
			540D-main	1.42	0	6.56	0.002	3	1									
			720D-main	1.18	0	2.26	0.069	4	0									
		00109446	30D-main	478.13	0	3.49	0.289	5	0	3.17	4.20	5.57	1.43	2.70	5.07			
			60D-main	486.54	0	4.42	0.932	5	0									
			90D-main	504.03	0	4.66	0.557	5	0									
		40089602	42D-main	323.75	0	1.27	0.694	4	0	2.31	3.77	6.15						
			91D-main	351.13	0	2.77	0.331	4	0									
			182D-main	409.52	0	4.54	0.510	4	0									
			364D-main	571.43	187.249	9.89	0.887	4	0									
		44842302	91D-duplicate	571.29	0	3.71	0.157	4	0	3.35	3.66	4.00						
			28D-main	477.60	0	0.12	0.341	3	1									
			56D-main	533.10	0	3.63	0.006	4	0									
			91D-main	528.12	0	3.52	0.890	4	0									
		00049236	90D-main	0.48	0	0.89	0.206	4	0	0.47	0.80	1.37						
			180D-main	0.49	0	0.31	0.565	4	0									
			360D-main	0.60	0	1.23	0.056	4	0									
			540D-main	0.70	0.39	5.41	0.140	4	0									
			720D-main	0.65	0	0.75	0.970	4	0									

**Terbufos Figure 1. - Potency Versus Duration of Exposure Graphs****BRAIN****PLASMA****RBC****M**


**Terbufos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**




### Terbufos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




## Terbufos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# TERBUFOS




## Terbufos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure



# TERBUFOS




## Terbufos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure




# TERBUFOS


49236 90 D - MAIN




49236 180 D - MAIN




49236 360 D - MAIN



49236 540 D - MAIN



49236 720 D - MAIN



# TERBUFOS

Terbufos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TERBUFOS

# TETRACHLORVINPHOS

## Tetrachlorvinphos

**Tetrachlorvinphos Table 1. - Toxicology Profile Table**

Tetrachlorvinphos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
41342001	82-2 (870.3200)	21-Day Dermal Toxicity–Rat	7844	0, 10, 100, 1000 mg/kg/day	Guideline	Rat/ Crl:CD-BR SD
43371201	82-1 (870.3100)	Subchronic Feeding–Rat	11295	0, 5, 100, 250 mg/kg/day	Guideline	Rat/ SD
00112525	83-2 (870.4200)	Chronic Feeding–Rat	002607 007181	0, 0.25, 1.25, 6.25, 100 mg/kg/day	Guideline	Rat/ Porton strain derived from Turnstall Lab
42980901	83-2 (870.4200)	Chronic Feeding–Rat	010884 010884 011295	0/0, 7.8/6.1, 79.7/62.1, 159.9/124.9 mg/kg/day (females/males)	Guideline	Rat/ SD

**Tetrachlorvinphos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure**

Tetrachlorvinphos																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	112525	728D-whole	0.77	0	6.40E-04	1.26E-06	5	0	4.92E-04	6.40E-04	8.35E-04	5.20E-04	6.71E-04	8.64E-04			
		42980901	364D-whole	10.46	8.46	0.02	0.889	4	0	4.54E-04	1.10E-03	2.67E-03						
			728D-whole	12.35	0	1.05E-03	0.215	4	0	9.81E-07	3.21E-03	10.50						
	43371201	91D-whole	14.17	9.21	3.21E-03	0.230	4	0										
	M	00112525	728D-whole	0.80	0	0.02	2.30E-08	3	2	0.01	0.02	0.03	0.01	0.02	0.03			
RBC	F	00112525	728D-main	0.92	0	1.96E-03	0.362	5	0	1.80E-03	1.96E-03	2.13E-03	1.52E-03	5.34E-03	1.88E-02			
		42980901	175D-main	692.24	0	7.34E-04	0.438	4	0	6.46E-04	3.37E-03	0.02						
			357D-main	839.92	0	1.40E-03	0.452	4	0									
			539D-main	1637.33	1110.17	0.05	0.534	4	0									
		43371201	721D-main	1461.09	1168.48	0.05	0.765	4	0	0.01	0.02	0.03						
	M	00112525	91D-main	1450.33	123.11	0.02	0.910	4	0			9.79E-04	2.46E-03	6.16E-03				
		43371201	91D-main	409.52	0	4.85E-03	0.613	4	0	3.54E-03	4.85E-03				6.64E-03			
Plasma	F	00112525	728D-main	1.82	0	9.07E-03	4.44E-06	5	0	8.71E-03	9.07E-03	9.45E-03	7.74E-03	1.28E-02	2.13E-02			
		42980901	175D-main	2498.59	0	2.53E-03	0.479	4	0	4.12E-03	9.78E-03	0.02						
			357D-main	2546.07	822.54	0.02	0.659	4	0									
			539D-main	2554.54	584.22	0.01	0.740	4	0									
		43371201	721D-main	2179.06	795.45	0.02	0.175	4	0	0.02	0.02	0.03						
	M	00112525	91D-main	2723.27	444.50	0.02	0.825	4	0			3.10E-03	3.51E-03	3.97E-03				
		42980901	728D-main	0.64	0	3.41E-03	6.32E-05	5	0	2.97E-03	3.41E-03				3.91E-03			
			357D-main	650.11	0	2.69E-03	0.262	4	0	2.78E-03	3.80E-03				5.20E-03			
			539D-main	793.65	0	4.61E-03	0.582	4	0									
		43371201	721D-main	978.57	0	3.15E-03	0.112	4	0									
		43371201	91D-main	586.22	282.89	0.01	0.456	4	0	2.77E-03	7.30E-03				0.02			

# TETRACHLORVINPHOS

## Tetrachlorvinphos Figure 1. - Potency Versus Duration of Exposure Graphs

BRAIN

PLASMA

RBC

F

M

# TETRACHLORVINPHOS

**Tetrachlorvinphos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

# TETRACHLORVINPHOS

**Tetrachlorvinphos Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

# TETRACHLORVINPHOS

**Tetrachlorvinphos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

# TETRACHLORVINPHOS

**Tetrachlorvinphos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

# TETRACHLORVINPHOS

**Tetrachlorvinphos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

# TETRACHLORVINPHOS

**Tetrachlorvinphos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure**

# TRIBUFOSS

## Tribufos

**Tribufos Table 1. - Toxicology Profile Table**

Tribufos						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/ Nonguideline	Species/ Strain
42335101	83-5 (870.4300)	Chronic Toxicity/Oncogenicity/Neurotoxicity	010119	0/0, 0.2/0.2, 2.3/1.8, 21.1/16.8 mg/kg/day (females/males)	Guideline	Rat/Fischer 344

**Tribufos Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure**

Tribufos																
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency	
Brain	F	42335101	364D-whole	13.75	0	0.05	0.111	4	0	0.01	0.03	0.08	0.01	0.03	0.08	
	M		721D-whole	12.82	0	0.01	0.388	3	1							
RBC	F	4233510	84D-main	2881.76	0	0.20	0.404	3	1	0.09	0.18	0.34	0.09	0.18	0.34	
			175D-main	2808.18	0	0.03	0.056	4	0							
			343D-main	2603.29	0	0.20	0.050	3	1							
			350D-main	2423.93	1060.55	0.37	3.30E-04	4	0							
			539D-main	2581.99	929.18	0.41	0.061	4	0							
			714D-main	2678.53	0	0.15	0.015	3	1							
Plasma	F	42335101	84D-main	2972.00	0	0.26	0.001	3	1	0.19	0.28	0.42	0.19	0.28	0.42	
			175D-main	3107.30	1100.91	0.12	0.682	4	0							
			343D-main	2783.99	1169.13	0.47	0.271	4	0							
			350D-main	2787.55	1198.43	0.42	0.236	4	0							
			539D-main	2769.25	858.71	0.44	0.466	4	0							
			714D-main	2751.86	0	0.18	0.068	3	1							
	M		84D-main	2399.16	449.95	0.57	0.806	4	0							
			175D-main	2911.56	510.03	0.60	0.850	4	0							
			343D-main	2734.17	0	0.39	Insufficient degrees of freedom to compute a GOF test		2	1	0.53	0.56	0.60	0.53	0.56	0.60
			350D-main	3036.77	480.05	0.61	0.844	4	0							
			539D-main	2941.82	609.83	0.55	0.678	4	0							
			714D-main	2384.60	409.86	0.56	0.460	4	0							
	M	42335101	84D-main	519.43	248.75	0.19	0.181	4	0	0.27	0.38	0.55	0.27	0.38	0.55	
			175D-main	639.21	308.49	0.33	0.021	4	0							
			343D-main	762.94	245.26	0.28	0.562	4	0							
			350D-main	807.03	329.14	0.38	0.716	4	0							
			539D-main	1024.67	330.87	0.66	0.063	4	0							
			714D-main	1219.42	260.22	0.65	0.312	4	0							

# TRIBUFOS

## Tribufos Figure 1. - Potency Versus Duration of Exposure Graphs

BRAIN

PLASMA

RBC

F

M

# TRIBUFOS

Tribufos Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRIBUFOS

Tribufos Figure 3. -Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRIBUFOS

Tribufos Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRIBUFOS

Tribufos Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRIBUFOS

Tribufos Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRIBUFOS

Tribufos Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

## Trichlorfon

**Trichlorfon Table 1. - Toxicology Profile Table**

Trichlorfon						
MRID #	Guideline No.	Study Type	HED Doc. No.	Dose	Guideline/Nonguideline	Species/Strain
40306901	82-2 (870.3200)	21-Day Dermal Toxicity–Rabbit	6476	0, 100, 300, 1000 mg/kg/day	Guideline	Rabbit
43871701	82-7 (870.6200)	Subchronic Dietary Neurotoxicity–Rat	13967	0/0, 6.9/6.1, 35.4/31.2, 188.7/164.7 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344
00152137	82-4 (870.3465)	21-Day Inhalation–Rat	004509 004915	0 (EtON/PEG), 12.7, 35.4, 103.5 mg/m <sup>3</sup>	Guideline	Rat/ SPF Wistar
41056201	83-5 (870.4300)	Combined Chronic Toxicity/ Carcinogenicity–Rat	9626	0/0, 5.8/4.5, 17.4/13.3, 109.2/85.7 mg/kg/day (females/males)	Guideline	Rat/ Fischer 344

**Trichlorfon Table 2. - Results of Dose Response Analysis: Exp.Parameter Estimates for Oral Route of Exposure**

Trichlorfon																		
Compartment	Sex	MRID #	Timepoint	A	B	m	GOF p-value	# Doses Used	# Doses Dropped	Lower 95% CL for MRID Potency	MRID Potency	Upper 95% CL for MRID Potency	Lower 95% CL for Compartment Potency	Compartment Potency	Upper 95% CL for Compartment Potency			
Brain	F	43871701	88D-whole	15.05	0	5.54E-03	0.109	4	0	5.27E-03	5.54E-03	5.81E-03	5.27E-03	5.54E-03	5.81E-03			
	M	43871701	87D-whole	14.67	0	1.74E-03	0.004	4	0	1.33E-03	1.74E-03	2.28E-03	1.33E-03	1.74E-03	2.28E-03			
RBC	F	41056201	98D-main	2819.14	0	4.54E-03	0.335	3	1	1.98E-03	2.61E-03	3.45E-03	2.16E-03	4.57E-03	9.67E-03			
			189D-main	2827.02	0	1.82E-03	0.010	4	0									
			364D-main	2734.80	0	3.14E-03	1.25E-05	4	0									
			553D-main	2723.11	0	2.28E-03	0.066	4	0									
			735D-main	2737.29	0	2.12E-03	0.665	4	0									
	M	41056201	25D-main	1528.28	79.55	0.01	0.966	4	0	7.30E-03	7.72E-03	8.16E-03	2.59E-03	4.79E-03	8.84E-03			
			88D-main	1530.58	0	7.68E-03	0.021	4	0									
		43871701	364D-main	2937.21	0	1.45E-03	4.76E-04	4	0	1.04E-03	3.22E-03	0.01						
			553D-main	2873.12	0	1.76E-03	1.91E-04	4	0									
			735D-main	2861.94	0	0.01	0.326	3	1									
Plasma	F	41056201	24D-main	1558.10	94.48	0.01	0.329	4	0	2.72E-03	5.64E-03	0.01	4.04E-03	0.01	0.02			
			87D-main	1387.93	0	3.67E-03	0.099	4	0									
			98D-main	2268.19	0	8.79E-03	0.163	3	1		4.45E-03	5.43E-03	6.63E-03					
			189D-main	2751.73	0	4.14E-03	0.314	4	0									
			364D-main	2845.91	0	5.37E-03	1.84E-04	4	0									
	M	41056201	553D-main	2572.88	0	5.42E-03	0.822	4	0	0.01	0.02	0.03	2.36E-03	4.99E-03	1.06E-02			
			735D-main	2530.13	1267.60	0.01	0.238	4	0									
			25D-main	1921.51	278.96	0.01	0.097	4	0									
		43871701	88D-main	2757.98	0	0.03	0.032	3	1									
			364D-main	735.61	0	2.32E-03	0.055	4	0	2.20E-03	2.96E-03	3.98E-03						
	M	41056201	553D-main	990.93	0	3.58E-03	1.20E-04	4	0									
			735D-main	1194.99	623.54	0.01	0.417	4	0									
			24D-main	568.01	0	8.67E-03	0.227	3	1		5.84E-03	8.74E-03	1.31E-02					
		43871701	87D-main	592.07	456.85	0.01	0.067	4	0									

# TRICHLORFON

## Trichlorfon Figure 1. - Potency Versus Duration of Exposure Graphs

BRAIN

PLASMA

RBC

F

M

# TRICHLORFON

Trichlorfon Figure 2. - Brain Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRICHLORFON

Trichlorfon Figure 3. - Brain Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRICHLORFON

Trichlorfon Figure 4. - Plasma Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRICHLORFON

Trichlorfon Figure 5. - Plasma Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRICHLORFON

Trichlorfon Figure 6. - RBC Female Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure

# TRICHLORFON

Trichlorfon Figure 7. - RBC Male Results of Dose-Response Analysis: Dose-Response Curves for Oral Route of Exposure